



Clinical trial results:

A phase III randomized, single-blind, controlled study to demonstrate the non-inferiority of co-administration of GSK Biologicals' 10-valent pneumococcal conjugate vaccine with Pediacel™ versus co-administration with Infanrix hexa™, when administered to infants as a three-dose primary vaccination course during the first six months of life and as a booster dose at 11-13 months of age.

Summary

EudraCT number	2007-004002-26
Trial protocol	NL
Global end of trial date	01 December 2010

Results information

Result version number	v2
This version publication date	12 March 2016
First version publication date	19 June 2015
Version creation reason	<ul style="list-style-type: none">• New data added to full data set Data for secondary endpoints have been added.

Trial information

Trial identification

Sponsor protocol code	110142, 111053
-----------------------	----------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00652951
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	GlaxoSmithKline Biologicals
Sponsor organisation address	Rue de l'Institut 89, Rixensart, Belgium, B-1330
Public contact	Clinical Trials Call Center, GlaxoSmithKline Biologicals, 044 2089-904466, GSKClinicalSupportHD@gsk.com
Scientific contact	Clinical Trials Call Center, GlaxoSmithKline Biologicals, 044 2089-904466, GSKClinicalSupportHD@gsk.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	12 December 2011
Is this the analysis of the primary completion data?	Yes
Primary completion date	12 May 2009
Global end of trial reached?	Yes
Global end of trial date	01 December 2010
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To demonstrate that GSK Biologicals' 10 valent pneumococcal conjugate vaccine when co-administered with DTPa-IPV-Hib (Pediace) (10Pn-PDC group) is non-inferior to co-administration with DTPa-IPV-Hib (Infanrix hexa) (10Pn-Hexa group), in terms of immune response to the 10 pneumococcal vaccine serotypes and to protein D, when administered as a three-dose primary vaccination course. Criteria for non-inferiority: For each of the 10 pneumococcal vaccine serotypes and protein D, non-inferiority will be demonstrated if the upper limit of the 2-sided 95% CI of the GMC ratio between groups (10Pn-Hexa group over 10Pn-PDC group), is lower than 2.

Protection of trial subjects:

All subjects were supervised for 30 min after vaccination/product administration with appropriate medical treatment readily available in case of a rare anaphylactic reaction. Vaccines/products were administered by qualified and trained personnel. Vaccines/products were administered only to eligible subjects that had no contraindications to any components of the vaccines/products. Also, all Intramuscular injections were administered into the anterolateral region of the thigh or into the deltoid. The buttock was not used for administration of vaccines because of the potential risk of injury to the sciatic nerve and the risk of decreased immunogenicity because of inadvertent subcutaneous injection or injection into deep fat tissue.

For all intramuscular injections, the needle was selected long enough to reach the muscle mass and prevent vaccine from seeping into subcutaneous tissue, but not so long as to involve underlying nerves and blood vessels or bone. Vaccinators were familiar with the anatomy of the area into which they are injecting vaccine. When appropriate, an individual decision on needle size and site of injection was made for each person on the basis of age, and the size of the muscle. Subjects were followed-up for 31 days after the last vaccination/product administration for adverse events following vaccination. Subjects were also followed during the entire study period for serious adverse events (SAEs).

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	01 April 2009
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Netherlands: 780
Worldwide total number of subjects	780
EEA total number of subjects	780

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	780
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

The study included a Primary (PRI) Phase, up to Month 3, followed by a Booster (BST) Phase, up to Month 9.

Pre-assignment

Screening details:

At screening the following was performed: informed consent was obtained and signed from subjects' parents/guardians, check for inclusion/exclusion criteria and contraindications/precautions was performed as regards to vaccination, and medical history of subjects was collected. Subjects' pre-vaccination body temperature was evaluated.

Period 1

Period 1 title	Primary Phase
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Single blind
Roles blinded	Subject

Arms

Are arms mutually exclusive?	Yes
Arm title	10Pn+DTPa-HBV-IPV/Hib Group

Arm description:

Subjects received 3 doses of 10Pn-PD-DiT (or GSK1024850A) vaccine co-administered with DTPa-HBV-IPV/Hib vaccine (Infanrix hexa by GSK Biologicals) at 2, 3 and 4 months of age (Study Months 0, 1, 2) and received a booster dose of each vaccine between 11 and 13 months of age (Study Month 9). All vaccines were administered intramuscularly in the right (10Pn-PD-DiT) or left (DTPa-HBV-IPV/Hib) thigh or deltoid.

Arm type	Experimental
Investigational medicinal product name	Synflorix
Investigational medicinal product code	10Pn-PD-DiT
Other name	10Pn-PD-DiT, 10Pn, GSK1024850A
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

3 doses at 2, 3 and 4 months of age (Study Months 0, 1, 2) followed by a booster dose between 11 and 13 months of age (Study Month 9). Vaccine was administered in the right thigh or deltoid.

Investigational medicinal product name	Infanrix hexa
Investigational medicinal product code	DTPa-HBV-IPV/Hib
Other name	DTPa-HBV-IPV/Hib
Pharmaceutical forms	Powder and solvent for suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

3 doses at 2, 3 and 4 months of age (Study Months 0, 1, 2) followed by a booster dose between 11 and 13 months of age (Study Month 9). Vaccine was administered in the left thigh or deltoid.

Arm title	10Pn+DTPa-IPV-Hib Group
------------------	-------------------------

Arm description:

Subjects received 3 doses of 10Pn-PD-DiT (or GSK1024850A) vaccine co-administered with DTPa-IPV-Hib vaccine (Pediatrix by Sanofi Pasteur MSD) at 2, 3 and 4 months of age (Study Months 0, 1, 2) and received a booster dose of each vaccine between 11 and 13 months of age (Study Month 9). All vaccines were administered intramuscularly in the right (10Pn-PD-DiT) or left (DTPa-IPV/Hib) thigh or deltoid.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Synflorix
Investigational medicinal product code	10Pn-PD-DiT
Other name	10Pn-PD-DiT, 10Pn, GSK1024850A
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

3 doses at 2, 3 and 4 months of age (Study Months 0, 1, 2) followed by a booster dose between 11 and 13 months of age (Study Month 9). Vaccine was administered in the right thigh or deltoid.

Investigational medicinal product name	Pediacel
Investigational medicinal product code	DTPa-IPV-Hib
Other name	DTPa-IPV-Hib
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

3 doses at 2, 3 and 4 months of age (Study Months 0, 1, 2) followed by a booster dose between 11 and 13 months of age (Study Month 9). Vaccine was administered in the left thigh or deltoid.

Arm title	7Pn+DTPa-IPV-Hib Group
------------------	------------------------

Arm description:

Subjects received 3 doses of 7Pn vaccine (or Prevenar by Pfizer [formerly Wyeth Lederle Vaccines S.A.]) co-administered with DTPa-IPV-Hib vaccine(Pediacel by Sanofi Pasteur MSD) at 2, 3 and 4 months of age (Study Months 0, 1, 2) and received a booster dose of each vaccine between 11 and 13 months of age (Study Month 9). All vaccines were administered intramuscularly in the right (7Pn) or left (DTPa-IPV-Hib; DTPa-HBV-IPV/Hib) thigh or deltoid.

Arm type	Experimental
Investigational medicinal product name	Prevenar
Investigational medicinal product code	
Other name	7Pn
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

3 doses at 2, 3 and 4 months of age (Study Months 0, 1, 2) followed by a booster dose between 11 and 13 months of age (Study Month 9). Vaccine was administered in the right thigh or deltoid.

Investigational medicinal product name	Pediacel
Investigational medicinal product code	DTPa-IPV-Hib
Other name	DTPa-IPV-Hib
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

3 doses at 2, 3 and 4 months of age (Study Months 0, 1, 2) followed by a booster dose between 11 and 13 months of age (Study Month 9). Vaccine was administered in the left thigh or deltoid.

Number of subjects in period 1	10Pn+DTPa-HBV-IPV/Hib Group	10Pn+DTPa-IPV-Hib Group	7Pn+DTPa-IPV-Hib Group
Started	260	260	260
Completed	260	260	260

Period 2

Period 2 title	Booster Phase
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Single blind
Roles blinded	Subject

Arms

Are arms mutually exclusive?	Yes
Arm title	10Pn+DTPa-HBV-IPV/Hib Group

Arm description:

Subjects received 3 doses of 10Pn-PD-DiT (or GSK1024850A) vaccine co-administered with DTPa-HBV-IPV/Hib vaccine (Infanrix hexa by GSK Biologicals) at 2, 3 and 4 months of age (Study Months 0, 1, 2) and received a booster dose of each vaccine between 11 and 13 months of age (Study Month 9). All vaccines were administered intramuscularly in the right (10Pn-PD-DiT) or left (DTPa-HBV-IPV/Hib) thigh or deltoid.

Arm type	Experimental
Investigational medicinal product name	Synflorix
Investigational medicinal product code	10Pn-PD-DiT
Other name	10Pn-PD-DiT, 10Pn, GSK1024850A
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

3 doses at 2, 3 and 4 months of age (Study Months 0, 1, 2) followed by a booster dose between 11 and 13 months of age (Study Month 9). Vaccine was administered in the right thigh or deltoid.

Investigational medicinal product name	Infanrix hexa
Investigational medicinal product code	DTPa-HBV-IPV/Hib
Other name	DTPa-HBV-IPV/Hib
Pharmaceutical forms	Powder and solvent for suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

3 doses at 2, 3 and 4 months of age (Study Months 0, 1, 2) followed by a booster dose between 11 and 13 months of age (Study Month 9). Vaccine was administered in the left thigh or deltoid.

Arm title	10Pn+DTPa-IPV-Hib Group
------------------	-------------------------

Arm description:

Subjects received 3 doses of 10Pn-PD-DiT (or GSK1024850A) vaccine co-administered with DTPa-IPV-Hib vaccine (Pediatrix by Sanofi Pasteur MSD) at 2, 3 and 4 months of age (Study Months 0, 1, 2) and received a booster dose of each vaccine between 11 and 13 months of age (Study Month 9). All vaccines were administered intramuscularly in the right (10Pn-PD-DiT) or left (DTPa-IPV/Hib) thigh or deltoid.

Arm type	Experimental
Investigational medicinal product name	Synflorix
Investigational medicinal product code	10Pn-PD-DiT
Other name	10Pn-PD-DiT, 10Pn, GSK1024850A
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

3 doses at 2, 3 and 4 months of age (Study Months 0, 1, 2) followed by a booster dose between 11 and 13 months of age (Study Month 9). Vaccine was administered in the right thigh or deltoid.

Investigational medicinal product name	Pediacel
Investigational medicinal product code	DTPa-IPV-Hib
Other name	DTPa-IPV-Hib
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

3 doses at 2, 3 and 4 months of age (Study Months 0, 1, 2) followed by a booster dose between 11 and 13 months of age (Study Month 9). Vaccine was administered in the left thigh or deltoid.

Arm title	7Pn+DTPa-IPV-Hib Group
------------------	------------------------

Arm description:

Subjects received 3 doses of 7Pn vaccine (or Prevenar by Pfizer [formerly Wyeth Lederle Vaccines S.A.]) co-administered with DTPa-IPV-Hib vaccine (Pediacel by Sanofi Pasteur MSD) at 2, 3 and 4 months of age (Study Months 0, 1, 2) and received a booster dose of each vaccine between 11 and 13 months of age (Study Month 9). All vaccines were administered intramuscularly in the right (10Pn; 7Pn) or left (DTPa-IPV-Hib; DTPa-HBV-IPV/Hib) thigh or deltoid.

Arm type	Experimental
Investigational medicinal product name	Prevenar
Investigational medicinal product code	
Other name	7Pn
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

3 doses at 2, 3 and 4 months of age (Study Months 0, 1, 2) followed by a booster dose between 11 and 13 months of age (Study Month 9). Vaccine was administered in the right thigh or deltoid.

Investigational medicinal product name	Pediacel
Investigational medicinal product code	DTPa-IPV-Hib
Other name	DTPa-IPV-Hib
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

3 doses at 2, 3 and 4 months of age (Study Months 0, 1, 2) followed by a booster dose between 11 and 13 months of age (Study Month 9). Vaccine was administered in the left thigh or deltoid.

Number of subjects in period 2^[1]	10Pn+DTPa-HBV-IPV/Hib Group	10Pn+DTPa-IPV-Hib Group	7Pn+DTPa-IPV-Hib Group
Started	257	259	258
Completed	256	258	258
Not completed	1	1	0
Adverse event, non-fatal	-	1	-
Not specified	1	-	-

Notes:

[1] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: 6 subjects did not join the study for the BST phase, 3 subjects from the 10Pn+DTPa-HBV-IPV/Hib Group, 1 subject from the 10Pn+DTPa-IPV-Hib Group and 2 subjects from the 7Pn+DTPa-IPV-Hib Group.

Baseline characteristics

Reporting groups

Reporting group title	10Pn+DTPa-HBV-IPV/Hib Group
Reporting group description:	
Subjects received 3 doses of 10Pn-PD-DiT (or GSK1024850A) vaccine co-administered with DTPa-HBV-IPV/Hib vaccine (Infanrix hexa by GSK Biologicals) at 2, 3 and 4 months of age (Study Months 0, 1, 2) and received a booster dose of each vaccine between 11 and 13 months of age (Study Month 9). All vaccines were administered intramuscularly in the right (10Pn-PD-DiT) or left (DTPa-HBV-IPV/Hib) thigh or deltoid.	
Reporting group title	10Pn+DTPa-IPV-Hib Group
Reporting group description:	
Subjects received 3 doses of 10Pn-PD-DiT (or GSK1024850A) vaccine co-administered with DTPa-IPV-Hib vaccine (PediaceL by Sanofi Pasteur MSD) at 2, 3 and 4 months of age (Study Months 0, 1, 2) and received a booster dose of each vaccine between 11 and 13 months of age (Study Month 9). All vaccines were administered intramuscularly in the right (10Pn-PD-DiT) or left (DTPa-IPV/Hib) thigh or deltoid.	
Reporting group title	7Pn+DTPa-IPV-Hib Group
Reporting group description:	
Subjects received 3 doses of 7Pn vaccine (or Prevenar by Pfizer [formerly Wyeth Lederle Vaccines S.A.]) co-administered with DTPa-IPV-Hib vaccine (PediaceL by Sanofi Pasteur MSD) at 2, 3 and 4 months of age (Study Months 0, 1, 2) and received a booster dose of each vaccine between 11 and 13 months of age (Study Month 9). All vaccines were administered intramuscularly in the right (7Pn) or left (DTPa-IPV-Hib; DTPa-HBV-IPV/Hib) thigh or deltoid.	

Reporting group values	10Pn+DTPa-HBV-IPV/Hib Group	10Pn+DTPa-IPV-Hib Group	7Pn+DTPa-IPV-Hib Group
Number of subjects	260	260	260
Age categorical Units: Subjects			
In utero			
Preterm newborn infants (gestational age < 37 wks)			
Newborns (0-27 days)			
Infants and toddlers (28 days-23 months)			
Children (2-11 years)			
Adolescents (12-17 years)			
Adults (18-64 years)			
From 65-84 years			
85 years and over			
Age continuous Units: weeks			
arithmetic mean	7.4	7.6	7.6
standard deviation	± 1.2	± 1.29	± 1.26
Gender categorical Units: Subjects			
Female	118	130	136
Male	142	130	124
Reporting group values	Total		
Number of subjects	780		

Age categorical			
Units: Subjects			
In utero	0		
Preterm newborn infants (gestational age < 37 wks)	0		
Newborns (0-27 days)	0		
Infants and toddlers (28 days-23 months)	0		
Children (2-11 years)	0		
Adolescents (12-17 years)	0		
Adults (18-64 years)	0		
From 65-84 years	0		
85 years and over	0		
Age continuous			
Units: weeks			
arithmetic mean			
standard deviation	-		
Gender categorical			
Units: Subjects			
Female	384		
Male	396		

End points

End points reporting groups

Reporting group title	10Pn+DTPa-HBV-IPV/Hib Group
Reporting group description: Subjects received 3 doses of 10Pn-PD-DiT (or GSK1024850A) vaccine co-administered with DTPa-HBV-IPV/Hib vaccine (Infanrix hexa by GSK Biologicals) at 2, 3 and 4 months of age (Study Months 0, 1, 2) and received a booster dose of each vaccine between 11 and 13 months of age (Study Month 9). All vaccines were administered intramuscularly in the right (10Pn-PD-DiT) or left (DTPa-HBV-IPV/Hib) thigh or deltoid.	
Reporting group title	10Pn+DTPa-IPV-Hib Group
Reporting group description: Subjects received 3 doses of 10Pn-PD-DiT (or GSK1024850A) vaccine co-administered with DTPa-IPV-Hib vaccine (Pediace1 by Sanofi Pasteur MSD) at 2, 3 and 4 months of age (Study Months 0, 1, 2) and received a booster dose of each vaccine between 11 and 13 months of age (Study Month 9). All vaccines were administered intramuscularly in the right (10Pn-PD-DiT) or left (DTPa-IPV/Hib) thigh or deltoid.	
Reporting group title	7Pn+DTPa-IPV-Hib Group
Reporting group description: Subjects received 3 doses of 7Pn vaccine (or Prevenar by Pfizer [formerly Wyeth Lederle Vaccines S.A.]) co-administered with DTPa-IPV-Hib vaccine(Pediace1 by Sanofi Pasteur MSD) at 2, 3 and 4 months of age (Study Months 0, 1, 2) and received a booster dose of each vaccine between 11 and 13 months of age (Study Month 9). All vaccines were administered intramuscularly in the right (7Pn) or left (DTPa-IPV-Hib; DTPa-HBV-IPV/Hib) thigh or deltoid.	
Reporting group title	10Pn+DTPa-HBV-IPV/Hib Group
Reporting group description: Subjects received 3 doses of 10Pn-PD-DiT (or GSK1024850A) vaccine co-administered with DTPa-HBV-IPV/Hib vaccine (Infanrix hexa by GSK Biologicals) at 2, 3 and 4 months of age (Study Months 0, 1, 2) and received a booster dose of each vaccine between 11 and 13 months of age (Study Month 9). All vaccines were administered intramuscularly in the right (10Pn-PD-DiT) or left (DTPa-HBV-IPV/Hib) thigh or deltoid.	
Reporting group title	10Pn+DTPa-IPV-Hib Group
Reporting group description: Subjects received 3 doses of 10Pn-PD-DiT (or GSK1024850A) vaccine co-administered with DTPa-IPV-Hib vaccine (Pediace1 by Sanofi Pasteur MSD) at 2, 3 and 4 months of age (Study Months 0, 1, 2) and received a booster dose of each vaccine between 11 and 13 months of age (Study Month 9). All vaccines were administered intramuscularly in the right (10Pn-PD-DiT) or left (DTPa-IPV/Hib) thigh or deltoid.	
Reporting group title	7Pn+DTPa-IPV-Hib Group
Reporting group description: Subjects received 3 doses of 7Pn vaccine (or Prevenar by Pfizer [formerly Wyeth Lederle Vaccines S.A.]) co-administered with DTPa-IPV-Hib vaccine(Pediace1 by Sanofi Pasteur MSD) at 2, 3 and 4 months of age (Study Months 0, 1, 2) and received a booster dose of each vaccine between 11 and 13 months of age (Study Month 9). All vaccines were administered intramuscularly in the right (10Pn; 7Pn) or left (DTPa-IPV-Hib; DTPa-HBV-IPV/Hib) thigh or deltoid.	

Primary: Antibody concentrations against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (Anti-1, -4, -5, -6B, -7F, -9V, -14, -18C, -19F and -23F) - Primary vaccination.

End point title	Antibody concentrations against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (Anti-1, -4, -5, -6B, -7F, -9V, -14, -18C, -19F and -23F) - Primary vaccination.
End point description: Anti-pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F antibody concentrations (Anti-1, -4, -5, -6B, -7F, -9V, -14, -18C, -19F and -23F) were measured by 22F-inhibition Enzyme-Linked Immunosorbent Assay (ELISA) Assay; calculated, expressed as geometric mean concentrations (GMCs) and tabulated. The seropositivity cut-off for the assay was ≥ 0.05 microgram per millilitre (microg/mL).	
End point type	Primary

End point timeframe:

At Month 3, aka one month after the administration of the third dose of pneumococcal conjugate vaccine

End point values	10Pn+DTPa-HBV-IPV/Hib Group	10Pn+DTPa-IPV-Hib Group	7Pn+DTPa-IPV-Hib Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	194	189	192	
Units: microg/mL				
geometric mean (confidence interval 95%)				
Anti-1 (N=181;178;178)	1.17 (1.02 to 1.33)	1.31 (1.16 to 1.48)	0.03 (0.03 to 0.03)	
Anti-4 (N=192;185;191)	1.61 (1.41 to 1.84)	1.59 (1.38 to 1.83)	2.44 (2.19 to 2.73)	
Anti-5 (N=187;181;178)	2.11 (1.88 to 2.37)	2.16 (1.92 to 2.43)	0.03 (0.03 to 0.03)	
Anti-6B (N=177;174;180)	0.33 (0.26 to 0.4)	0.35 (0.28 to 0.43)	0.41 (0.34 to 0.51)	
Anti-7F (N=192;187;183)	1.7 (1.52 to 1.9)	1.77 (1.57 to 1.99)	0.04 (0.03 to 0.04)	
Anti-9V (N=185;186;187)	1.4 (1.2 to 1.63)	1.47 (1.29 to 1.68)	2.14 (1.91 to 2.4)	
Anti-14 (N=192;187;192)	3.38 (2.99 to 3.81)	3.33 (2.93 to 3.78)	3.64 (3.24 to 4.1)	
Anti-18C (N=194;189;191)	1.73 (1.45 to 2.05)	1.07 (0.92 to 1.25)	2.1 (1.83 to 2.4)	
Anti-19F (N=189;183;189)	2.07 (1.73 to 2.48)	1.96 (1.64 to 2.34)	3.04 (2.71 to 3.42)	
Anti-23F (N=179;175;184)	0.5 (0.41 to 0.6)	0.54 (0.44 to 0.66)	1.24 (1.04 to 1.47)	

Statistical analyses

Statistical analysis title	Immune response non-inferiority - serotype 1
----------------------------	--

Statistical analysis description:

The 2-sided 95% CI of the geometric mean concentration (GMC) ratio between the 10Pn+DTPa-HBV-IPV/Hib and 10Pn+DTPa-IPV-Hib groups (10Pn+DTPa-HBV-IPV/Hib Group over 10Pn+DTPa-IPV-Hib Group), at one month after Dose 3 of pneumococcal vaccine, was computed for each of the 10 pneumococcal vaccine serotypes and protein D. This statistical method concerns pneumococcal vaccine serotype 1.

Comparison groups	10Pn+DTPa-HBV-IPV/Hib Group v 10Pn+DTPa-IPV-Hib Group
Number of subjects included in analysis	383
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[1]
Parameter estimate	GMC ratio
Point estimate	0.89
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.74
upper limit	1.07

Notes:

[1] - The non-inferiority objective was reached if the upper limit of the 2-sided 95% CI of the GMC ratio for between groups (10Pn+DTPa-HBV-IPV/Hib Group over 10Pn+DTPa-IPV-Hib Group), was lower than 2, for each of the 10 pneumococcal serotypes and protein D.

Statistical analysis title	Immune response non-inferiority - serotype 4
-----------------------------------	--

Statistical analysis description:

The 2-sided 95% CI of the geometric mean concentration (GMC) ratio between the 10Pn+DTPa-HBV-IPV/Hib and 10Pn+DTPa-IPV-Hib groups (10Pn+DTPa-HBV-IPV/Hib Group over 10Pn+DTPa-IPV-Hib Group), at one month after Dose 3 of pneumococcal vaccine, was computed for each of the 10 pneumococcal vaccine serotypes and protein D. This statistical method concerns pneumococcal vaccine serotype 4.

Comparison groups	10Pn+DTPa-HBV-IPV/Hib Group v 10Pn+DTPa-IPV-Hib Group
Number of subjects included in analysis	383
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[2]
Parameter estimate	GMC ratio
Point estimate	1.01
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.84
upper limit	1.23

Notes:

[2] - The non-inferiority objective was reached if the upper limit of the 2-sided 95% CI of the GMC ratio for between groups (10Pn+DTPa-HBV-IPV/Hib Group over 10Pn+DTPa-IPV-Hib Group), was lower than 2, for each of the 10 pneumococcal serotypes and protein D.

Statistical analysis title	Immune response non-inferiority - serotype 5
-----------------------------------	--

Statistical analysis description:

The 2-sided 95% CI of the geometric mean concentration (GMC) ratio between the 10Pn+DTPa-HBV-IPV/Hib and 10Pn+DTPa-IPV-Hib groups (10Pn+DTPa-HBV-IPV/Hib Group over 10Pn+DTPa-IPV-Hib Group), at one month after Dose 3 of pneumococcal vaccine, was computed for each of the 10 pneumococcal vaccine serotypes and protein D. This statistical method concerns pneumococcal vaccine serotype 5.

Comparison groups	10Pn+DTPa-HBV-IPV/Hib Group v 10Pn+DTPa-IPV-Hib Group
Number of subjects included in analysis	383
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[3]
Parameter estimate	GMC ratio
Point estimate	0.98
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.83
upper limit	1.15

Notes:

[3] - The non-inferiority objective was reached if the upper limit of the 2-sided 95% CI of the GMC ratio for between groups (10Pn+DTPa-HBV-IPV/Hib Group over 10Pn+DTPa-IPV-Hib Group), was lower than 2, for each of the 10 pneumococcal serotypes and protein D.

Statistical analysis title	Immune response non-inferiority - serotype 6B
-----------------------------------	---

Statistical analysis description:

The 2-sided 95% CI of the geometric mean concentration (GMC) ratio between the 10Pn+DTPa-HBV-IPV/Hib and 10Pn+DTPa-IPV-Hib groups (10Pn+DTPa-HBV-IPV/Hib Group over 10Pn+DTPa-IPV-Hib Group), at one month after Dose 3 of pneumococcal vaccine, was computed for each of the 10 pneumococcal vaccine serotypes and protein D. This statistical method concerns pneumococcal vaccine

serotype 6B.

Comparison groups	10Pn+DTPa-HBV-IPV/Hib Group v 10Pn+DTPa-IPV-Hib Group
Number of subjects included in analysis	383
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[4]
Parameter estimate	GMC ratio
Point estimate	0.93
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.69
upper limit	1.26

Notes:

[4] - The non-inferiority objective was reached if the upper limit of the 2-sided 95% CI of the GMC ratio for between groups (10Pn+DTPa-HBV-IPV/Hib Group over 10Pn+DTPa-IPV-Hib Group), was lower than 2, for each of the 10 pneumococcal serotypes and protein D.

Statistical analysis title	Immune response non-inferiority - serotype 7F
-----------------------------------	---

Statistical analysis description:

The 2-sided 95% CI of the geometric mean concentration (GMC) ratio between the 10Pn+DTPa-HBV-IPV/Hib and 10Pn+DTPa-IPV-Hib groups (10Pn+DTPa-HBV-IPV/Hib Group over 10Pn+DTPa-IPV-Hib Group), at one month after Dose 3 of pneumococcal vaccine, was computed for each of the 10 pneumococcal vaccine serotypes and protein D. This statistical method concerns pneumococcal vaccine serotype 7F.

Comparison groups	10Pn+DTPa-HBV-IPV/Hib Group v 10Pn+DTPa-IPV-Hib Group
Number of subjects included in analysis	383
Analysis specification	Pre-specified
Analysis type	non-inferiority
Parameter estimate	GMC ratio
Point estimate	0.96
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.82
upper limit	1.13

Statistical analysis title	Immune response non-inferiority - serotype 9V
-----------------------------------	---

Statistical analysis description:

The 2-sided 95% CI of the geometric mean concentration (GMC) ratio between the 10Pn+DTPa-HBV-IPV/Hib and 10Pn+DTPa-IPV-Hib groups (10Pn+DTPa-HBV-IPV/Hib Group over 10Pn+DTPa-IPV-Hib Group), at one month after Dose 3 of pneumococcal vaccine, was computed for each of the 10 pneumococcal vaccine serotypes and protein D. This statistical method concerns pneumococcal vaccine serotype 9V.

Comparison groups	10Pn+DTPa-HBV-IPV/Hib Group v 10Pn+DTPa-IPV-Hib Group
Number of subjects included in analysis	383
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[5]
Parameter estimate	GMC ratio
Point estimate	0.95

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.78
upper limit	1.16

Notes:

[5] - The non-inferiority objective was reached if the upper limit of the 2-sided 95% CI of the GMC ratio for between groups (10Pn+DTPa-HBV-IPV/Hib Group over 10Pn+DTPa-IPV-Hib Group), was lower than 2, for each of the 10 pneumococcal serotypes and protein D.

Statistical analysis title	Immune response non-inferiority - serotype 14
-----------------------------------	---

Statistical analysis description:

The 2-sided 95% CI of the geometric mean concentration (GMC) ratio between the 10Pn+DTPa-HBV-IPV/Hib and 10Pn+DTPa-IPV-Hib groups (10Pn+DTPa-HBV-IPV/Hib Group over 10Pn+DTPa-IPV-Hib Group), at one month after Dose 3 of pneumococcal vaccine, was computed for each of the 10 pneumococcal vaccine serotypes and protein D. This statistical method concerns pneumococcal vaccine serotype 14.

Comparison groups	10Pn+DTPa-HBV-IPV/Hib Group v 10Pn+DTPa-IPV-Hib Group
Number of subjects included in analysis	383
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[6]
Parameter estimate	GMC ratio
Point estimate	1.01

Confidence interval

level	95 %
sides	2-sided
lower limit	0.85
upper limit	1.21

Notes:

[6] - The non-inferiority objective was reached if the upper limit of the 2-sided 95% CI of the GMC ratio for between groups (10Pn+DTPa-HBV-IPV/Hib Group over 10Pn+DTPa-IPV-Hib Group), was lower than 2, for each of the 10 pneumococcal serotypes and protein D.

Statistical analysis title	Immune response non-inferiority - serotype 18C
-----------------------------------	--

Statistical analysis description:

The 2-sided 95% CI of the geometric mean concentration (GMC) ratio between the 10Pn+DTPa-HBV-IPV/Hib and 10Pn+DTPa-IPV-Hib groups (10Pn+DTPa-HBV-IPV/Hib Group over 10Pn+DTPa-IPV-Hib Group), at one month after Dose 3 of pneumococcal vaccine, was computed for each of the 10 pneumococcal vaccine serotypes and protein D. This statistical method concerns pneumococcal vaccine serotype 18C.

Comparison groups	10Pn+DTPa-HBV-IPV/Hib Group v 10Pn+DTPa-IPV-Hib Group
Number of subjects included in analysis	383
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[7]
Method	Regression, Cox
Parameter estimate	GMC ratio
Point estimate	1.61

Confidence interval

level	95 %
sides	2-sided
lower limit	1.28
upper limit	2.03

Notes:

[7] - The non-inferiority objective was reached if the upper limit of the 2-sided 95% CI of the GMC ratio for between groups (10Pn+DTPa-HBV-IPV/Hib Group over 10Pn+DTPa-IPV-Hib Group), was lower than 2, for each of the 10 pneumococcal serotypes and protein D.

Statistical analysis title	Immune response non-inferiority - serotype 19F
-----------------------------------	--

Statistical analysis description:

The 2-sided 95% CI of the geometric mean concentration (GMC) ratio between the 10Pn+DTPa-HBV-IPV/Hib and 10Pn+DTPa-IPV-Hib groups (10Pn+DTPa-HBV-IPV/Hib Group over 10Pn+DTPa-IPV-Hib Group), at one month after Dose 3 of pneumococcal vaccine, was computed for each of the 10 pneumococcal vaccine serotypes and protein D. This statistical method concerns pneumococcal vaccine serotype 19F.

Comparison groups	10Pn+DTPa-HBV-IPV/Hib Group v 10Pn+DTPa-IPV-Hib Group
Number of subjects included in analysis	383
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[8]
Parameter estimate	GMC ratio
Point estimate	1.06
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.82
upper limit	1.36

Notes:

[8] - The non-inferiority objective was reached if the upper limit of the 2-sided 95% CI of the GMC ratio for between groups (10Pn+DTPa-HBV-IPV/Hib Group over 10Pn+DTPa-IPV-Hib Group), was lower than 2, for each of the 10 pneumococcal serotypes and protein D.

Statistical analysis title	Immune response non-inferiority - serotype 23F
-----------------------------------	--

Statistical analysis description:

The 2-sided 95% CI of the geometric mean concentration (GMC) ratio between the 10Pn+DTPa-HBV-IPV/Hib and 10Pn+DTPa-IPV-Hib groups (10Pn+DTPa-HBV-IPV/Hib Group over 10Pn+DTPa-IPV-Hib Group), at one month after Dose 3 of pneumococcal vaccine, was computed for each of the 10 pneumococcal vaccine serotypes and protein D. This statistical method concerns pneumococcal vaccine serotype 23F.

Comparison groups	10Pn+DTPa-HBV-IPV/Hib Group v 10Pn+DTPa-IPV-Hib Group
Number of subjects included in analysis	383
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[9]
Parameter estimate	GMC ratio
Point estimate	0.92
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.7
upper limit	1.23

Notes:

[9] - The non-inferiority objective was reached if the upper limit of the 2-sided 95% CI of the GMC ratio for between groups (10Pn+DTPa-HBV-IPV/Hib Group over 10Pn+DTPa-IPV-Hib Group), was lower than 2, for each of the 10 pneumococcal serotypes and protein D.

Primary: Antibody concentration against protein D (PD) - Primary vaccination.

End point title	Antibody concentration against protein D (PD) - Primary vaccination.
-----------------	--

End point description:

Anti-PD antibody concentrations were calculated, expressed as geometric mean concentrations (GMCs) and tabulated. The seropositivity cut-off for the assay was ≥ 100 Enzyme-Linked ImmunoSorbent Assay (ELISA) units per millilitre (EL.U/mL).

End point type	Primary
End point timeframe:	
At Month 3, aka one month after the administration of the third dose of pneumococcal conjugate vaccine	

End point values	10Pn+DTPa-HBV-IPV/Hib Group	10Pn+DTPa-IPV-Hib Group	7Pn+DTPa-IPV-Hib Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	195	189	182	
Units: EL.U/mL				
geometric mean (confidence interval 95%)				
Anti-PD	1580 (1409.5 to 1771.1)	1743 (1560.2 to 1947.2)	69.7 (63 to 77.1)	

Statistical analyses

Statistical analysis title	Immune response non-inferiority - protein D
Statistical analysis description:	
The 2-sided 95% CI of the geometric mean concentration (GMC) ratio between the 10Pn+DTPa-HBV-IPV/Hib and 10Pn+DTPa-IPV-Hib groups (10Pn+DTPa-HBV-IPV/Hib Group over 10Pn+DTPa-IPV-Hib Group), at one month after Dose 3 of pneumococcal vaccine, was computed for each of the 10 pneumococcal vaccine serotypes and protein D. This statistical method concerns protein D.	
Comparison groups	10Pn+DTPa-HBV-IPV/Hib Group v 10Pn+DTPa-IPV-Hib Group
Number of subjects included in analysis	384
Analysis specification	Pre-specified
Analysis type	non-inferiority
Parameter estimate	GMC ratio
Point estimate	0.91
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.77
upper limit	1.06

Secondary: Number of subjects with antibody concentrations against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (Anti-1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F) ≥ 0.2 µg/mL - Primary vaccination.

End point title	Number of subjects with antibody concentrations against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (Anti-1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F) ≥ 0.2 µg/mL - Primary vaccination.
-----------------	--

End point description:

A seropositive subject was a subject whose antibody concentration was greater than or equal to the cut-off value ≥ 0.05 µg/mL.

End point type	Secondary
----------------	-----------

End point timeframe:

One month after the administration of the third vaccine dose

End point values	10Pn+DTPa- HBV-IPV/Hib Group	10Pn+DTPa- IPV-Hib Group	7Pn+DTPa- IPV-Hib Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	194	189	192	
Units: Subjects				
Anti-1 (N=181;178;178)	174	176	5	
Anti-4 (N=192;185;191)	188	180	189	
Anti-5 (N=187;181;178)	187	179	0	
Anti-6B (N=177;174;180)	122	113	124	
Anti-7F (N=192;187;183)	190	186	11	
Anti-9V (N=185;186;187)	176	181	184	
Anti-14 (N=192;187;192)	191	187	192	
Anti-18C (N=194;189;191)	183	178	187	
Anti-19F (N=189;183;189)	180	174	189	
Anti-23F (N=179;175;184)	134	133	171	

Statistical analyses

No statistical analyses for this end point

Secondary: Opsonophagocytic activity (OPA) titers against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F - Primary vaccination.

End point title	Opsonophagocytic activity (OPA) titers against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F - Primary vaccination.
-----------------	--

End point description:

A seropositive subject was a subject whose antibody titers were greater than or equal to the cut-off value ≥ 8

End point type	Secondary
----------------	-----------

End point timeframe:

One month after the administration of the third vaccine dose

End point values	10Pn+DTPa- HBV-IPV/Hib Group	10Pn+DTPa- IPV-Hib Group	7Pn+DTPa- IPV-Hib Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	139	135	132	
Units: Titers				
geometric mean (confidence interval 95%)				
Opsono-1 (N=132;126;125)	20.7 (15.6 to 27.6)	20.8 (15.8 to 27.4)	4.7 (4.1 to 5.2)	

Opsono-4 (N=133;132;129)	592.9 (475.9 to 738.7)	600.4 (492.2 to 732.3)	838.4 (718.7 to 978.2)	
Opsono-5 (N=138;134;132)	54.8 (44 to 68.4)	60.1 (48.2 to 74.8)	4.2 (3.9 to 4.6)	
Opsono-6B (N=129;130;123)	261.3 (176 to 388)	296.4 (198 to 443.7)	633 (419 to 956.4)	
Opsono-7F (N=130;127;114)	2063.3 (1691.7 to 2516.6)	2136.1 (1707.9 to 2671.5)	18.4 (12.1 to 28)	
Opsono-9V (N=132;129;125)	863.6 (687.6 to 1084.7)	1277.7 (1053.3 to 1550.1)	1194 (1009.5 to 1412.1)	
Opsono-14 (N=134;135;127)	990.4 (820.6 to 1195.5)	1086.4 (899.6 to 1311.9)	1373.3 (1040.4 to 1812.7)	
Opsono-18C (N=133;129;129)	122.6 (89.4 to 168.2)	84.2 (60.9 to 116.5)	213.6 (163.6 to 278.8)	
Opsono-19F (N=137;133;130)	133 (98.1 to 180.2)	143.8 (108.6 to 190.3)	39.2 (30.6 to 50.4)	
Opsono-23F (N=139;133;130)	847.4 (626.5 to 1146.3)	1089 (800.2 to 1482)	3703.4 (3119.4 to 4396.8)	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with antibody concentrations against pneumococcal cross-reactive serotypes 6A and 19A (Anti-6A and 19A) ≥ 0.2 µg/mL - Primary vaccination.

End point title	Number of subjects with antibody concentrations against pneumococcal cross-reactive serotypes 6A and 19A (Anti-6A and 19A) ≥ 0.2 µg/mL - Primary vaccination.
-----------------	--

End point description:

A seropositive subject was a subject whose antibody concentration was greater than or equal to the cut-off value ≥ 0.05 µg/mL.

End point type	Secondary
----------------	-----------

End point timeframe:

One month after the administration of the third vaccine dose

End point values	10Pn+DTPa- HBV-IPV/Hib Group	10Pn+DTPa- IPV-Hib Group	7Pn+DTPa- IPV-Hib Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	185	177	183	
Units: Subjects				
Anti-6A (N=185;176;183)	58	51	41	
Anti-19A (N=180;177;180)	56	50	40	

Statistical analyses

No statistical analyses for this end point

Secondary: Antibody concentrations against pneumococcal cross-reactive serotypes 6A and 19A (Anti-6A and 19A) - Primary vaccination.

End point title	Antibody concentrations against pneumococcal cross-reactive serotypes 6A and 19A (Anti-6A and 19A) - Primary vaccination.
-----------------	---

End point description:

A seropositive subject was a subject whose antibody concentration was greater than or equal to the cut-off value ≥ 0.05 $\mu\text{g/mL}$.

End point type	Secondary
----------------	-----------

End point timeframe:

One month after the administration of the third vaccine dose

End point values	10Pn+DTPa- HBV-IPV/Hib Group	10Pn+DTPa- IPV-Hib Group	7Pn+DTPa- IPV-Hib Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	185	177	183	
Units: $\mu\text{g/mL}$				
geometric mean (confidence interval 65%)				
Anti-6A (N=185;176;183)	0.1 (0.08 to 0.12)	0.1 (0.09 to 0.12)	0.08 (0.06 to 0.09)	
Anti-19A (N=180;177;180)	0.1 (0.09 to 0.13)	0.09 (0.08 to 0.11)	0.08 (0.07 to 0.1)	

Statistical analyses

No statistical analyses for this end point

Secondary: Opsonophagocytic activity (OPA) titers against pneumococcal cross-reactive serotypes 6A and 19A - Primary vaccination.

End point title	Opsonophagocytic activity (OPA) titers against pneumococcal cross-reactive serotypes 6A and 19A - Primary vaccination.
-----------------	--

End point description:

A seropositive subject was a subject whose antibody titers were greater than or equal to the cut-off value ≥ 8

End point type	Secondary
----------------	-----------

End point timeframe:

One month after the administration of the third vaccine dose

End point values	10Pn+DTPa- HBV-IPV/Hib Group	10Pn+DTPa- IPV-Hib Group	7Pn+DTPa- IPV-Hib Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	135	129	130	
Units: Titres				
geometric mean (confidence interval 95%)				
Opsono-6A (N=128;120;121)	23.2 (16.1 to 33.6)	25.4 (17.1 to 37.8)	33 (21.4 to 50.8)	
Opsono-19A (N=135;129;130)	9 (6.9 to 11.7)	8 (6.3 to 10.2)	4.9 (4.4 to 5.4)	

Statistical analyses

No statistical analyses for this end point

Secondary: Concentrations of antibodies against diphtheria and tetanus toxoids (anti-D and T) - Primary vaccination.

End point title	Concentrations of antibodies against diphtheria and tetanus toxoids (anti-D and T) - Primary vaccination.
-----------------	---

End point description:

A seroprotected subject was a subject whose antibody concentration was greater than or equal to the cut-off value ≥ 0.1 IU/mL

End point type	Secondary
----------------	-----------

End point timeframe:

One month after the administration of the third vaccine dose

End point values	10Pn+DTPa- HBV-IPV/Hib Group	10Pn+DTPa- IPV-Hib Group	7Pn+DTPa- IPV-Hib Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	187	180	189	
Units: IU/mL				
geometric mean (confidence interval 95%)				
Anti-diphtheria (N=185;176;187)	1.475 (1.307 to 1.664)	1.078 (0.939 to 1.237)	1.077 (0.949 to 1.222)	
Anti-tetanus (N=187;180;189)	2.873 (2.622 to 3.147)	1.702 (1.528 to 1.897)	0.934 (0.837 to 1.043)	

Statistical analyses

No statistical analyses for this end point

Secondary: Anti-polyribosyl-ribitol phosphate (anti-PRP) antibody concentrations - Primary vaccination.

End point title	Anti-polyribosyl-ribitol phosphate (anti-PRP) antibody
-----------------	--

End point description:

A seroprotected subject was a subject whose antibody concentration was greater than or equal to the cut-off value $\geq 0.15 \mu\text{g/mL}$ and $\geq 1.0 \mu\text{g/mL}$.

End point type	Secondary
----------------	-----------

End point timeframe:

One month after the administration of the third vaccine dose

End point values	10Pn+DTPa- HBV-IPV/Hib Group	10Pn+DTPa- IPV-Hib Group	7Pn+DTPa- IPV-Hib Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	189	179	188	
Units: $\mu\text{g/mL}$				
geometric mean (confidence interval 95%)				
Anti-PRP (N=189;179;188)	2.139 (1.766 to 2.59)	4.796 (3.829 to 6.007)	2.219 (1.724 to 2.857)	

Statistical analyses

No statistical analyses for this end point

Secondary: Anti-pertussis toxoid (anti-PT), anti-filamentous haemagglutinin (anti-FHA) and anti-pertactin (anti-PRN) antibody concentrations - Primary vaccination.

End point title	Anti-pertussis toxoid (anti-PT), anti-filamentous haemagglutinin (anti-FHA) and anti-pertactin (anti-PRN) antibody concentrations - Primary vaccination.
-----------------	--

End point description:

A seropositive subject was a subject whose antibody concentration was greater than or equal to the cut-off value $\geq 5 \text{ EL.U/mL}$.

End point type	Secondary
----------------	-----------

End point timeframe:

One month after the administration of the third vaccine dose

End point values	10Pn+DTPa- HBV-IPV/Hib Group	10Pn+DTPa- IPV-Hib Group	7Pn+DTPa- IPV-Hib Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	187	180	188	
Units: EL.U/mL				
geometric mean (confidence interval 95%)				
Anti-PT (N=187;180;188)	42.7 (39.1 to 46.6)	36.4 (33.4 to 39.8)	40.1 (37 to 43.6)	

Anti-FHA (N=183;172;183)	145.6 (130.4 to 162.5)	100.8 (89.6 to 113.5)	100.5 (89.9 to 112.4)	
Anti-PRN (N=187;180;188)	97.6 (86.8 to 109.7)	40.1 (34.8 to 46.1)	45.1 (39.3 to 51.7)	

Statistical analyses

No statistical analyses for this end point

Secondary: Anti-hepatitis B surface antigen (anti-HBs) antibody concentrations - Primary vaccination.

End point title	Anti-hepatitis B surface antigen (anti-HBs) antibody concentrations - Primary vaccination.
-----------------	--

End point description:

A seroprotected subject was a subject whose antibody ChemiLuminescence ImmunoAssay (CLIA) concentration was greater than or equal to the cut-off value ≥ 10 mIU/mL.

Note: investigations on the quality of some serology assays revealed that the anti-HBs ELISA overestimated concentration between 10-100 mIU/mL while values > 100 mIU/mL were confirmed valid. Therefore, all available samples at one month post-dose III and one month post-dose IV timepoints for which the anti-HBs antibody concentration was between 10-100 mIU/mL by in-house ELISA, were retested by the commercial assay Centaur™, an FDA-approved and CE-marked CLIA with a cut-off defining seropositivity of 6.2 mIU/mL. Anti-HBs seroprotection was redefined as in-house ELISA concentration > 100 mIU/mL or CLIA concentration > 10 mIU/mL.

End point type	Secondary
----------------	-----------

End point timeframe:

One month after the administration of the third vaccine dose

End point values	10Pn+DTPa-HBV-IPV/Hib Group	10Pn+DTPa-IPV-Hib Group	7Pn+DTPa-IPV-Hib Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	111	112	113	
Units: mIU/mL				
geometric mean (confidence interval 95%)				
Anti-HBs (N=111;112;113)	356.9 (279.4 to 455.8)	14 (11.6 to 16.9)	11.5 (9.8 to 13.5)	

Statistical analyses

No statistical analyses for this end point

Secondary: Anti-polio types 1, 2 and 3 titers - Primary vaccination.

End point title	Anti-polio types 1, 2 and 3 titers - Primary vaccination.
-----------------	---

End point description:

A seroprotected subject was a subject whose antibody titers were greater than or equal to the cut-off value ≥ 8 .

End point type	Secondary
----------------	-----------

End point timeframe:

One month after the administration of the third vaccine dose

End point values	10Pn+DTPa- HBV-IPV/Hib Group	10Pn+DTPa- IPV-Hib Group	7Pn+DTPa- IPV-Hib Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	156	150	149	
Units: Titers				
geometric mean (confidence interval 95%)				
Anti-polio 1 (N=155;150;149)	27.2 (21.7 to 34.1)	16 (13 to 19.7)	18.1 (14.8 to 22.1)	
Anti-polio 2 (N=156;149;149)	37.1 (29.1 to 47.4)	29 (23 to 36.6)	23.2 (18.5 to 29.1)	
Anti-polio 3 (N=156;148;149)	47.3 (35.8 to 62.4)	34.2 (27 to 43.4)	26.7 (21.5 to 33)	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with antibody concentrations against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (Anti-1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F) ≥ 0.2 $\mu\text{g/mL}$ - Booster vaccination.

End point title	Number of subjects with antibody concentrations against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (Anti-1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F) ≥ 0.2 $\mu\text{g/mL}$ - Booster vaccination.
-----------------	--

End point description:

A seropositive subject was a subject whose antibody concentration was greater than or equal to the cut-off value ≥ 0.05 $\mu\text{g/mL}$.

End point type	Secondary
----------------	-----------

End point timeframe:

Prior (PRE) to and one month after (POST) the administration of the booster dose

End point values	10Pn+DTPa- HBV-IPV/Hib Group	10Pn+DTPa- IPV-Hib Group	7Pn+DTPa- IPV-Hib Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	190	198	202	
Units: Subjects				
Anti-1, PRE(N=178;185;198)	84	92	6	
Anti-4, PRE (N=174;181;194)	136	147	148	
Anti-5, PRE (N=181;181;198)	142	152	3	
Anti-6B, PRE (N=175;180;192)	117	127	62	
Anti-7F, PRE(N=176;181;195)	165	164	5	

Anti-9V, PRE(N=180;180;196)	168	168	176	
Anti-14, PRE (N=183;184;199)	170	172	190	
Anti-18C, PRE (N=179;181;194)	152	143	151	
Anti-19F, PRE(N=172;177;197)	149	157	109	
Anti-23F, PRE (N=180;182;196)	123	140	108	
Anti-1, POST(N=187;196;199)	187	195	7	
Anti-4, POST (N=187;194;198)	187	194	198	
Anti-5, POST (N=186;191;195)	185	191	4	
Anti-6B, POST (N=186;193;199)	176	181	192	
Anti-7F, POST (N=189;198;199)	189	198	8	
Anti-9V, POST (N=188;197;202)	188	197	202	
Anti-14, POST (N=190;198;201)	190	197	198	
Anti-18C, POST (N=189;197;200)	188	196	200	
Anti-19F, POST(N=183;194;196)	180	191	196	
Anti-23F, POST (N=185;194;199)	179	190	194	

Statistical analyses

No statistical analyses for this end point

Secondary: Antibody concentrations against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (Anti-1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F) - Booster vaccination.

End point title	Antibody concentrations against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (Anti-1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F) - Booster vaccination.
-----------------	--

End point description:

A seropositive subject was a subject whose antibody concentration was greater than or equal to the cut-off value ≥ 0.05 µg/mL.

End point type	Secondary
----------------	-----------

End point timeframe:

Prior (PRE) to and one month after (POST) the administration of the booster dose

End point values	10Pn+DTPa-HBV-IPV/Hib Group	10Pn+DTPa-IPV-Hib Group	7Pn+DTPa-IPV-Hib Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	190	198	202	
Units: µg/mL				
geometric mean (confidence interval 95%)				
Anti-1, PRE(N=178;185;198)	0.2 (0.17 to 0.22)	0.22 (0.19 to 0.26)	0.03 (0.03 to 0.04)	
Anti-4, PRE (N=174;181;194)	0.39 (0.34 to 0.46)	0.43 (0.37 to 0.5)	0.38 (0.34 to 0.43)	
Anti-5, PRE (N=181;181;198)	0.41 (0.36 to 0.47)	0.42 (0.37 to 0.48)	0.03 (0.03 to 0.04)	
Anti-6B, PRE (N=175;180;192)	0.3 (0.25 to 0.36)	0.32 (0.27 to 0.38)	0.13 (0.11 to 0.16)	

Anti-7F, PRE(N=176;181;195)	0.6 (0.54 to 0.68)	0.62 (0.55 to 0.71)	0.03 (0.03 to 0.03)
Anti-9V, PRE(N=180;180;196)	0.68 (0.6 to 0.78)	0.76 (0.66 to 0.89)	0.55 (0.49 to 0.62)
Anti-14, PRE (N=183;184;199)	1.06 (0.9 to 1.26)	1.14 (0.95 to 1.36)	1.55 (1.35 to 1.79)
Anti-18C, PRE (N=179;181;194)	0.58 (0.49 to 0.68)	0.43 (0.36 to 0.5)	0.4 (0.35 to 0.45)
Anti-19F, PRE(N=172;177;197)	0.79 (0.64 to 0.99)	0.9 (0.73 to 1.11)	0.31 (0.25 to 0.37)
Anti-23F, PRE (N=180;182;196)	0.33 (0.27 to 0.39)	0.38 (0.32 to 0.46)	0.26 (0.22 to 0.3)
Anti-1, POST(N=187;196;199)	2.16 (1.89 to 2.46)	2.5 (2.19 to 2.86)	0.03 (0.03 to 0.04)
Anti-4, POST (N=187;194;198)	3.04 (2.7 to 3.42)	3.29 (2.89 to 3.73)	4.01 (3.53 to 4.56)
Anti-5, POST (N=186;191;195)	3.27 (2.9 to 3.7)	3.27 (2.9 to 3.68)	0.04 (0.03 to 0.04)
Anti-6B, POST (N=186;193;199)	1.45 (1.23 to 1.71)	1.41 (1.19 to 1.67)	2.52 (2.15 to 2.96)
Anti-7F, POST (N=189;198;199)	3.79 (3.4 to 4.23)	4.06 (3.63 to 4.54)	0.03 (0.03 to 0.04)
Anti-9V, POST (N=188;197;202)	3.96 (3.58 to 4.39)	4.23 (3.78 to 4.74)	6.05 (5.38 to 6.8)
Anti-14, POST (N=190;198;201)	4.59 (4.06 to 5.19)	4.95 (4.38 to 5.6)	7.31 (6.37 to 8.39)
Anti-18C, POST (N=189;197;200)	6.36 (5.56 to 7.27)	4.63 (4.09 to 5.25)	5.08 (4.47 to 5.78)
Anti-19F, POST(N=183;194;196)	5.45 (4.72 to 6.3)	5.8 (5.04 to 6.68)	2.4 (2.14 to 2.7)
Anti-23F, POST (N=185;194;199)	2.32 (1.98 to 2.71)	2.6 (2.24 to 3.02)	5.32 (4.49 to 6.31)

Statistical analyses

No statistical analyses for this end point

Secondary: Opsonophagocytic activity (OPA) titers against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F - Booster vaccination.

End point title	Opsonophagocytic activity (OPA) titers against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F - Booster vaccination.
-----------------	--

End point description:

A seropositive subject was a subject whose antibody titers were greater than or equal to the cut-off value ≥ 8

End point type	Secondary
----------------	-----------

End point timeframe:

Prior (PRE) to and one month after (POST) the administration of the booster dose

End point values	10Pn+DTPa- HBV-IPV/Hib Group	10Pn+DTPa- IPV-Hib Group	7Pn+DTPa- IPV-Hib Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	156	154	168	
Units: Titers				
geometric mean (confidence interval 95%)				
Opsono-1, PRE (N=149;152;168)	5.5 (4.7 to 6.4)	5.6 (4.7 to 6.7)	5 (4.4 to 5.8)	
Opsono-4, PRE (N=145;150;164)	11.3 (8.6 to 14.9)	15.3 (11.3 to 20.6)	12.3 (9.3 to 16.2)	
Opsono-5, PRE (N=148;151;166)	7.2 (6.1 to 8.5)	7 (6 to 8.1)	4.3 (4 to 4.6)	
Opsono-6B, PRE (N=141;138;153)	52 (34.8 to 77.7)	96.7 (63.1 to 148)	27.4 (18.6 to 40.3)	
Opsono-7F, PRE (N=146;150;146)	818.9 (642.2 to 1044.3)	754.3 (598.4 to 950.8)	138.1 (91.2 to 209.2)	
Opsono-9V, PRE (N=143;147;159)	267.2 (212.7 to 335.8)	338.7 (264.8 to 433.2)	149.5 (112.4 to 198.9)	
Opsono-14, PRE (N=143;144;161)	117.3 (82.9 to 165.9)	142.5 (101.3 to 200.4)	156 (114.5 to 212.5)	
Opsono-18C, PRE (N=139;148;162)	8.2 (6.2 to 10.8)	6.8 (5.3 to 8.5)	7 (5.7 to 8.7)	
Opsono-19F, PRE (N=149;149;167)	13.8 (10.6 to 18.1)	15.4 (11.8 to 20.2)	7.8 (6.2 to 9.9)	
Opsono-23F, PRE (N=143;143;162)	314.1 (198.6 to 496.7)	350.4 (229.8 to 534.2)	338.9 (219.9 to 522.3)	
Opsono-1, POST (N=156;154;164)	208.8 (160.6 to 271.7)	221.4 (165.1 to 297)	4.6 (4.2 to 5.1)	
Opsono-4, POST (N=155;152;164)	1046.8 (865.8 to 1265.7)	1121.6 (909.4 to 1383.3)	2335.8 (1946.3 to 2803.3)	
Opsono-5, POST (N=152;151;164)	149.3 (119.2 to 187)	132.4 (103.8 to 168.9)	4.1 (4 to 4.3)	
Opsono-6B, POST (N=153;149;160)	681.4 (514.6 to 902.1)	763.3 (581.9 to 1001.3)	1807.5 (1408 to 2320.3)	
Opsono-7F, POST (N=154;152;153)	3936.5 (3413.2 to 4540)	3976 (3390.2 to 4663.1)	129.1 (85.9 to 193.9)	
Opsono-9V, POST (N=153;151;163)	2512.9 (2213.1 to 2853.2)	2257.6 (1974.3 to 2581.5)	3889.5 (3260.1 to 4640.2)	
Opsono-14, POST (N=154;154;164)	1534.2 (1290.9 to 1823.3)	1896.3 (1591.3 to 2259.7)	1867.9 (1540.5 to 2265.1)	
Opsono-18C, POST (N=153;152;159)	720.7 (597.5 to 869.4)	385.9 (303.5 to 490.8)	660.4 (520.9 to 837.3)	
Opsono-19F, POST (N=153;149;164)	435.7 (336.3 to 564.5)	475.4 (377.8 to 598.1)	123.2 (95.9 to 158.2)	
Opsono-23F, POST (N=152;154;164)	2895.4 (2276.1 to 3683.1)	2895.3 (2419.3 to 3465)	12418.7 (10171.8 to 15161.9)	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with antibody concentrations against pneumococcal cross-reactive serotypes 6A and 19A (Anti-6A and 19A) \geq 0.2 μ g/mL - Booster

vaccination.

End point title	Number of subjects with antibody concentrations against pneumococcal cross-reactive serotypes 6A and 19A (Anti-6A and 19A) $\geq 0.2 \mu\text{g/mL}$ - Booster vaccination.
-----------------	---

End point description:

A seropositive subject was a subject whose antibody concentration was greater than or equal to the cut-off value $\geq 0.05 \mu\text{g/mL}$.

End point type	Secondary
----------------	-----------

End point timeframe:

Prior (PRE) to and one month after (POST) the administration of the booster dose

End point values	10Pn+DTPa-HBV-IPV/Hib Group	10Pn+DTPa-IPV-Hib Group	7Pn+DTPa-IPV-Hib Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	187	196	201	
Units: Subjects				
Anti-6A, PRE (N=181;185;193)	50	56	28	
Anti-19A, PRE (N=182;184;199)	61	63	29	
Anti-6A, POST (N=187;196;201)	135	142	160	
Anti-19A, POST (N=187;195;200)	130	139	97	

Statistical analyses

No statistical analyses for this end point

Secondary: Antibody concentrations against pneumococcal cross-reactive serotypes 6A and 19A (Anti-6A and 19A) - Booster vaccination.

End point title	Antibody concentrations against pneumococcal cross-reactive serotypes 6A and 19A (Anti-6A and 19A) - Booster vaccination.
-----------------	---

End point description:

A seropositive subject was a subject whose antibody concentration was greater than or equal to the cut-off value $\geq 0.05 \mu\text{g/mL}$.

End point type	Secondary
----------------	-----------

End point timeframe:

Prior (PRE) to and one month after (POST) the administration of the booster dose

End point values	10Pn+DTPa-HBV-IPV/Hib Group	10Pn+DTPa-IPV-Hib Group	7Pn+DTPa-IPV-Hib Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	187	196	201	
Units: $\mu\text{g/mL}$				
geometric mean (confidence interval 95%)				

Anti-6A, PRE (N=181;185;193)	0.1 (0.09 to 0.12)	0.11 (0.09 to 0.13)	0.06 (0.05 to 0.07)	
Anti-19A, PRE (N=182;184;199)	0.12 (0.1 to 0.15)	0.12 (0.09 to 0.14)	0.06 (0.05 to 0.07)	
Anti-6A, POST (N=187;196;201)	0.45 (0.36 to 0.55)	0.49 (0.4 to 0.61)	0.71 (0.58 to 0.88)	
Anti-19A, POST (N=187;195;200)	0.5 (0.39 to 0.63)	0.52 (0.41 to 0.66)	0.21 (0.17 to 0.25)	

Statistical analyses

No statistical analyses for this end point

Secondary: Opsonophagocytic activity (OPA) titers against pneumococcal cross-reactive serotypes 6A and 19A - Booster vaccination.

End point title	Opsonophagocytic activity (OPA) titers against pneumococcal cross-reactive serotypes 6A and 19A - Booster vaccination.
-----------------	--

End point description:

A seropositive subject was a subject whose antibody titers were greater than or equal to the cut-off value ≥ 8

End point type	Secondary
----------------	-----------

End point timeframe:

Prior (PRE) to and one month after (POST) the administration of the booster dose

End point values	10Pn+DTPa-HBV-IPV/Hib Group	10Pn+DTPa-IPV-Hib Group	7Pn+DTPa-IPV-Hib Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	151	148	167	
Units: Titers				
geometric mean (confidence interval 95%)				
Opsono-6A, PRE (N=128;135;151)	23.3 (15.7 to 34.6)	30.7 (20.8 to 45.2)	15.5 (11.1 to 21.6)	
Opsono-19A, PRE (N=148;148;167)	5.7 (4.6 to 7)	5.5 (4.6 to 6.5)	5.5 (4.6 to 6.5)	
Opsono-6A, POST (N=145;142;160)	143.3 (99.1 to 207.3)	197.1 (138 to 281.3)	493.3 (357.1 to 681.6)	
Opsono-19A, POST (N=151;148;162)	34.9 (24.8 to 49.2)	24.6 (17.7 to 34.3)	7.7 (6.2 to 9.5)	

Statistical analyses

No statistical analyses for this end point

Secondary: Concentrations of antibodies against protein D (Anti-PD) - Booster vaccination.

End point title	Concentrations of antibodies against protein D (Anti-PD) - Booster vaccination.
-----------------	---

End point description:

A seropositive subject was a subject whose antibody concentration was greater than or equal to the cut-off value ≥ 100 EL.U/mL.

End point type	Secondary
----------------	-----------

End point timeframe:

Prior (PRE) to and one month after (POST) the administration of the booster dose

End point values	10Pn+DTPa- HBV-IPV/Hib Group	10Pn+DTPa- IPV-Hib Group	7Pn+DTPa- IPV-Hib Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	189	198	201	
Units: EL.U/mL				
geometric mean (confidence interval 95%)				
Anti-PD, PRE (N=182;189;195)	421 (370.3 to 478.5)	520.5 (455.8 to 594.3)	80.8 (73.1 to 89.4)	
Anti-PD, POST (N=189;198;201)	1715 (1510.3 to 1947.5)	1936.8 (1710.5 to 2193.2)	84.1 (76 to 93.1)	

Statistical analyses

No statistical analyses for this end point

Secondary: Concentrations of antibodies against diphtheria and tetanus toxoids (anti-D and T) - Booster vaccination.

End point title	Concentrations of antibodies against diphtheria and tetanus toxoids (anti-D and T) - Booster vaccination.
-----------------	---

End point description:

A seroprotected subject was a subject whose antibody concentration was greater than or equal to the cut-off value ≥ 0.1 IU/mL.

End point type	Secondary
----------------	-----------

End point timeframe:

Prior (PRE) to and one month after (POST) the administration of the booster dose

End point values	10Pn+DTPa- HBV-IPV/Hib Group	10Pn+DTPa- IPV-Hib Group	7Pn+DTPa- IPV-Hib Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	186	194	197	
Units: IU/mL				
geometric mean (confidence interval 95%)				
Anti-diphtheria, PRE (N=175;179;192)	0.235 (0.205 to 0.27)	0.232 (0.203 to 0.264)	0.266 (0.235 to 0.301)	

Anti-tetanus, PRE (N=175;180;193)	0.728 (0.656 to 0.809)	0.536 (0.477 to 0.603)	0.232 (0.202 to 0.267)	
Anti-diphtheria, POST (N=186;194;197)	4.061 (3.601 to 4.58)	3.226 (2.866 to 3.632)	4.882 (4.425 to 5.386)	
Anti-tetanus, POST (N=186;194;197)	8.628 (7.867 to 9.462)	5.989 (5.461 to 6.568)	3.248 (2.859 to 3.69)	

Statistical analyses

No statistical analyses for this end point

Secondary: Anti-polyribosyl-ribitol phosphate (anti-PRP) antibody concentrations - Booster vaccination.

End point title	Anti-polyribosyl-ribitol phosphate (anti-PRP) antibody concentrations - Booster vaccination.
-----------------	--

End point description:

A seroprotected subject was a subject whose antibody concentration was greater than or equal to the cut-off value $\geq 0.15 \mu\text{g/mL}$ and $\geq 1.0 \mu\text{g/mL}$.

End point type	Secondary
----------------	-----------

End point timeframe:

Prior (PRE) to and one month after (POST) the administration of the booster dose

End point values	10Pn+DTPa-HBV-IPV/Hib Group	10Pn+DTPa-IPV-Hib Group	7Pn+DTPa-IPV-Hib Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	184	192	197	
Units: $\mu\text{g/mL}$				
geometric mean (confidence interval 95%)				
Anti-PRP, PRE (N=174;179;193)	0.475 (0.386 to 0.585)	0.855 (0.682 to 1.072)	0.371 (0.298 to 0.461)	
Anti-PRP, POST (N=184;192;197)	19.331 (16.144 to 23.147)	39.383 (32.617 to 47.551)	23.676 (18.944 to 29.591)	

Statistical analyses

No statistical analyses for this end point

Secondary: Anti-pertussis toxoid (anti-PT), anti-filamentous haemagglutinin (anti-FHA) and anti-pertactin (anti-PRN) antibody concentrations - Booster vaccination.

End point title	Anti-pertussis toxoid (anti-PT), anti-filamentous haemagglutinin (anti-FHA) and anti-pertactin (anti-PRN) antibody concentrations - Booster vaccination.
-----------------	--

End point description:

A seropositive subject was a subject whose antibody concentration was greater than or equal to the cut-off value $\geq 5 \text{ EL.U/mL}$.

End point type	Secondary
End point timeframe:	
Prior (PRE) to and one month after (POST) the administration of the booster dose	

End point values	10Pn+DTPa- HBV-IPV/Hib Group	10Pn+DTPa- IPV-Hib Group	7Pn+DTPa- IPV-Hib Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	186	194	197	
Units: EL.U/mL				
geometric mean (confidence interval 95%)				
Anti-PT, PRE (N=174;176;189)	7.4 (6.6 to 8.4)	6 (5.4 to 6.7)	6.6 (5.9 to 7.3)	
Anti-FHA, PRE (N=175;179;191)	34 (29.4 to 39.4)	35.3 (30.8 to 40.6)	34.7 (30.1 to 39.9)	
Anti-PRN, PRE (N=175;179;192)	14.1 (12.3 to 16.2)	6.8 (5.9 to 7.9)	8.6 (7.4 to 10)	
Anti-PT, POST (N=186;194;196)	53.5 (48.3 to 59.2)	47.4 (42.9 to 52.5)	54.8 (48.9 to 61.4)	
Anti-FHA, POST (N=184;192;194)	343.5 (308 to 383.1)	135.7 (121.2 to 151.9)	140 (123.2 to 159.1)	
Anti-PRN, POST (N=186;193;197)	281.7 (247.2 to 321)	97.8 (85.4 to 112)	106.4 (91.5 to 123.8)	

Statistical analyses

No statistical analyses for this end point

Secondary: Anti-hepatitis B surface antigen (anti-HBs) antibody concentrations - Booster vaccination.

End point title	Anti-hepatitis B surface antigen (anti-HBs) antibody concentrations - Booster vaccination.
-----------------	--

End point description:

A seroprotected subject was a subject whose antibody ChemiLuminescence ImmunoAssay (CLIA) concentration was greater than or equal to the cut-off value ≥ 10 mIU/mL.

Note: investigations on the quality of some serology assays revealed that the anti-HBs ELISA overestimated concentration between 10-100 mIU/mL while values > 100 mIU/mL were confirmed valid. Therefore, all available samples at one month post-dose III and one month post-dose IV timepoints for which the anti-HBs antibody concentration was between 10-100 mIU/mL by in-house ELISA, were retested by the commercial assay Centaur™, an FDA-approved and CE-marked CLIA with a cut-off defining seropositivity of 6.2 mIU/mL. Anti-HBs seroprotection was redefined as in-house ELISA concentration > 100 mIU/mL or CLIA concentration > 10 mIU/mL.

End point type	Secondary
End point timeframe:	
Prior (PRE) to and one month after (POST) the administration of the booster dose	

End point values	10Pn+DTPa- HBV-IPV/Hib Group	10Pn+DTPa- IPV-Hib Group	7Pn+DTPa- IPV-Hib Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	125	124	135	
Units: mIU/mL				
geometric mean (confidence interval 95%)				
Anti-HBs, PRE (121;124;135)	142.1 (113.4 to 178.1)	9.9 (8.8 to 11.2)	9.9 (8.8 to 11.2)	
Anti-HBs, POST (125;123;135)	1981 (1552 to 2528.7)	8.6 (7.6 to 9.9)	8.5 (7.6 to 9.5)	

Statistical analyses

No statistical analyses for this end point

Secondary: Anti-polio types 1, 2 and 3 titers - Booster vaccination.

End point title	Anti-polio types 1, 2 and 3 titers - Booster vaccination.
-----------------	---

End point description:

A seroprotected subject was a subject whose antibody titers were greater than or equal to the cut-off value ≥ 8 .

End point type	Secondary
----------------	-----------

End point timeframe:

Prior (PRE) to and one month after (POST) the administration of the booster dose

End point values	10Pn+DTPa- HBV-IPV/Hib Group	10Pn+DTPa- IPV-Hib Group	7Pn+DTPa- IPV-Hib Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	167	173	182	
Units: Titers				
geometric mean (confidence interval 95%)				
Anti-polio 1, PRE (N=156;166;182)	8.3 (7 to 10)	7.3 (6.3 to 8.4)	7 (6.1 to 8)	
Anti-polio 2, PRE (N=156;164;182)	13.4 (10.8 to 16.6)	10.6 (8.8 to 12.7)	10.4 (8.9 to 12.2)	
Anti-polio 3, PRE (N=156;166;180)	11.3 (9.3 to 13.9)	9 (7.5 to 10.7)	8.7 (7.4 to 10.3)	
Anti-polio 1, POST (N=166;173;170)	370.7 (289.8 to 474.2)	177.5 (135.8 to 231.9)	221.2 (171.5 to 285.3)	
Anti-polio 2, POST (N=167;173;169)	710.8 (588 to 859.3)	338.8 (272.7 to 420.8)	481.4 (391 to 592.7)	
Anti-polio 3, POST (N=167;172;170)	631.5 (495.7 to 804.4)	311.9 (240.4 to 404.6)	348.3 (263.6 to 460.2)	

Statistical analyses

Secondary: Number of subjects with booster vaccine response against pertussis toxoid (PT), filamentous haemagglutinin (FHA) and pertactin (PRN) antibodies - Booster vaccination.

End point title	Number of subjects with booster vaccine response against pertussis toxoid (PT), filamentous haemagglutinin (FHA) and pertactin (PRN) antibodies - Booster vaccination.
-----------------	--

End point description:

A booster responder to PT/FHA/PRN was defined as a subject with antibodies concentration ≥ 5 EL.U/mL against PT/FHA/PRN in subjects who were initially seronegative for anti-PT/FHA/PRN antibodies (i.e., subjects with anti-PT/FHA/PRN antibody concentrations < 5 EL.U/mL), or antibody concentration ≥ 2 fold the pre-vaccination antibody concentration in subjects who were initially seropositive (i.e., subjects with anti-PT/FHA/PRN antibody concentrations ≥ 5 EL.U/mL).

End point type	Secondary
----------------	-----------

End point timeframe:

One month after (POST) the administration of the booster dose

End point values	10Pn+DTPa-HBV-IPV/Hib Group	10Pn+DTPa-IPV-Hib Group	7Pn+DTPa-IPV-Hib Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	135	143	150	
Units: Subjects				
Anti-PT, S- seronegative (N=40;48;48)	40	47	48	
Anti-PT, S+ seropositive (N=99;95;105)	95	94	98	
Anti-FHA, S- seronegative (N=4;1;2)	4	1	2	
Anti-FHA, S+ seropositive (N=135;143;150)	128	119	125	
Anti-PRN, S- seronegative (N=18;56;53)	18	56	51	
Anti-PRN, S+ seropositive (N=122;89;102)	122	88	101	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with antibody concentrations against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (Anti-1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F) ≥ 0.2 µg/mL - 12 months after booster dose.

End point title	Number of subjects with antibody concentrations against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (Anti-1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F) ≥ 0.2 µg/mL - 12 months after booster dose.
-----------------	--

End point description:

A seropositive subject was a subject whose antibody concentration was greater than or equal to the cut-off value ≥ 0.05 µg/mL.

End point type	Secondary
----------------	-----------

End point timeframe:

12 months after the administration of the booster dose (at 23-25 months of age, M12)

End point values	10Pn+DTPa- HBV-IPV/Hib Group	10Pn+DTPa- IPV-Hib Group	7Pn+DTPa- IPV-Hib Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	166	169	177	
Units: Subjects				
Anti-1, M12 (N=163;166;173)	106	108	6	
Anti-4, M12 (N=163;167;173)	101	102	130	
Anti-5, M12 (N=163;163;170)	129	129	10	
Anti-6B, M12 (N=162;164;173)	94	96	133	
Anti-7F, M12 (N=163;165;170)	157	157	15	
Anti-9V, M12 (N=165;168;173)	155	157	160	
Anti-14, M12 (N=166;169;177)	149	156	173	
Anti-18C, M12 (N=164;167;174)	160	155	161	
Anti-19F, M12 (N=164;165;171)	158	158	134	
Anti-23F, M12(N=162;166;172)	123	126	153	

Statistical analyses

No statistical analyses for this end point

Secondary: Antibody concentrations against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (Anti-1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F) - 12 months after booster dose.

End point title	Antibody concentrations against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (Anti-1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F) - 12 months after booster dose.
-----------------	---

End point description:

A seropositive subject was a subject whose antibody concentration was greater than or equal to the cut-off value $\geq 0.05 \mu\text{g/mL}$.

End point type	Secondary
----------------	-----------

End point timeframe:

12 months after the administration of the booster dose (at 23-25 months of age, M12)

End point values	10Pn+DTPa- HBV-IPV/Hib Group	10Pn+DTPa- IPV-Hib Group	7Pn+DTPa- IPV-Hib Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	166	169	177	
Units: $\mu\text{g/mL}$				
geometric mean (confidence interval 95%)				

Anti-1, M12 (N=163;166;173)	0.3 (0.26 to 0.35)	0.32 (0.28 to 0.38)	0.04 (0.03 to 0.04)	
Anti-4, M12 (N=163;167;173)	0.25 (0.22 to 0.29)	0.29 (0.25 to 0.34)	0.36 (0.32 to 0.42)	
Anti-5, M12 (N=163;163;170)	0.45 (0.39 to 0.53)	0.47 (0.39 to 0.55)	0.05 (0.04 to 0.05)	
Anti-6B, M12 (N=162;164;173)	0.3 (0.25 to 0.36)	0.32 (0.26 to 0.4)	0.46 (0.38 to 0.56)	
Anti-7F, M12 (N=163;165;170)	0.72 (0.63 to 0.81)	0.73 (0.64 to 0.84)	0.04 (0.03 to 0.05)	
Anti-9V, M12 (N=165;168;173)	0.74 (0.63 to 0.88)	0.78 (0.66 to 0.91)	0.81 (0.7 to 0.94)	
Anti-14, M12 (N=166;169;177)	0.73 (0.62 to 0.86)	0.85 (0.73 to 0.99)	1.28 (1.1 to 1.48)	
Anti-18C, M12 (N=164;167;174)	1.03 (0.89 to 1.19)	0.64 (0.56 to 0.74)	0.66 (0.59 to 0.75)	
Anti-19F, M12 (N=164;165;171)	1.48 (1.22 to 1.8)	1.46 (1.2 to 1.78)	0.76 (0.59 to 0.98)	
Anti-23F, M12(N=162;166;172)	0.51 (0.41 to 0.63)	0.52 (0.42 to 0.63)	1.01 (0.83 to 1.24)	

Statistical analyses

No statistical analyses for this end point

Secondary: Opsonophagocytic activity (OPA) titers against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F - 12 months after booster dose.

End point title	Opsonophagocytic activity (OPA) titers against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F - 12 months after booster dose.
-----------------	---

End point description:

A seropositive subject was a subject whose antibody titers were greater than or equal to the cut-off value ≥ 8 .

End point type	Secondary
----------------	-----------

End point timeframe:

12 months after the administration of the booster dose (at 23-25 months of age, M12)

End point values	10Pn+DTPa-HBV-IPV/Hib Group	10Pn+DTPa-IPV-Hib Group	7Pn+DTPa-IPV-Hib Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	159	152	165	
Units: Titers				
geometric mean (confidence interval 95%)				
Opsono-1, M12 (N=159;150;162)	10.9 (8.5 to 14.1)	9.9 (7.8 to 12.5)	4.3 (3.9 to 4.7)	
Opsono-4, M12 (N=154;147;160)	12 (9.1 to 15.9)	15.5 (11 to 21.7)	45.2 (30.8 to 66.5)	
Opsono-5, M12 (N=159;152;165)	12.9 (10.4 to 16)	13.7 (11 to 17.1)	4.1 (3.9 to 4.3)	

Opsono-6B, M12 (N=139;137;152)	77.7 (48.8 to 123.8)	137.6 (83.5 to 226.6)	220 (145.4 to 332.8)	
Opsono-7F, M12 (N=142;136;143)	1982.9 (1568.8 to 2506.2)	2205.6 (1833.4 to 2653.4)	738.1 (549.8 to 990.7)	
Opsono-9V, M12 (N=143;135;147)	465.9 (324.2 to 669.5)	470 (325.8 to 677.9)	476.2 (317.8 to 713.5)	
Opsono-14, M12 (N=128;121;149)	93.1 (60 to 144.4)	151.6 (97.7 to 235.4)	238.7 (163.5 to 348.6)	
Opsono-18C, M12 (N=135;133;151)	21.6 (15.2 to 30.6)	12.5 (8.9 to 17.6)	15.3 (10.9 to 21.3)	
Opsono-19F, M12 (N=148;150;162)	31.1 (22.6 to 42.8)	32.9 (23.8 to 45.4)	15.1 (11 to 20.6)	
Opsono-23F, M12 (N=146;140;161)	366.5 (218.3 to 615.3)	706.1 (443.5 to 1124.3)	3879.8 (2774.4 to 5425.5)	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with antibody concentrations against pneumococcal cross-reactive serotypes 6A and 19A (Anti-6A and 19A) ≥ 0.2 $\mu\text{g/mL}$ - 12 months after booster dose.

End point title	Number of subjects with antibody concentrations against pneumococcal cross-reactive serotypes 6A and 19A (Anti-6A and 19A) ≥ 0.2 $\mu\text{g/mL}$ - 12 months after booster dose.
-----------------	--

End point description:

A seropositive subject was a subject whose antibody concentration was greater than or equal to the cut-off value ≥ 0.05 $\mu\text{g/mL}$.

End point type	Secondary
----------------	-----------

End point timeframe:

12 months after the administration of the booster dose (at 23-25 months of age, M12)

End point values	10Pn+DTPa-HBV-IPV/Hib Group	10Pn+DTPa-IPV-Hib Group	7Pn+DTPa-IPV-Hib Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	165	166	176	
Units: Subjects				
Anti-6A, M12 (N=163;166;174)	54	57	92	
Anti-19A, M12 (N=165;166;176)	120	97	80	

Statistical analyses

No statistical analyses for this end point

Secondary: Antibody concentrations against pneumococcal cross-reactive serotypes

6A and 19A (Anti-6A and 19A) - 12 months after booster dose.

End point title	Antibody concentrations against pneumococcal cross-reactive serotypes 6A and 19A (Anti-6A and 19A) - 12 months after booster dose.
-----------------	--

End point description:

A seropositive subject was a subject whose antibody concentration was greater than or equal to the cut-off value $\geq 0.05 \mu\text{g/mL}$.

End point type	Secondary
----------------	-----------

End point timeframe:

12 months after the administration of the booster dose (at 23-25 months of age, M12)

End point values	10Pn+DTPa- HBV-IPV/Hib Group	10Pn+DTPa- IPV-Hib Group	7Pn+DTPa- IPV-Hib Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	165	166	176	
Units: $\mu\text{g/mL}$				
geometric mean (confidence interval 95%)				
Anti-6A, M12 (N=163;166;174)	0.14 (0.12 to 0.17)	0.15 (0.12 to 0.19)	0.22 (0.18 to 0.27)	
Anti-19A, M12 (N=165;166; 176)	0.43 (0.35 to 0.53)	0.29 (0.23 to 0.36)	0.21 (0.16 to 0.27)	

Statistical analyses

No statistical analyses for this end point

Secondary: Opsonophagocytic activity (OPA) titers against pneumococcal cross-reactive serotypes 6A and 19A - 12 months after booster dose.

End point title	Opsonophagocytic activity (OPA) titers against pneumococcal cross-reactive serotypes 6A and 19A - 12 months after booster dose.
-----------------	---

End point description:

A seropositive subject was a subject whose antibody titers were greater than or equal to the cut-off value ≥ 8

End point type	Secondary
----------------	-----------

End point timeframe:

12 months after the administration of the booster dose (at 23-25 months of age, M12)

End point values	10Pn+DTPa- HBV-IPV/Hib Group	10Pn+DTPa- IPV-Hib Group	7Pn+DTPa- IPV-Hib Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	150	146	158	
Units: Titers				
geometric mean (confidence interval 95%)				
Opsono-6A, M12 (N=126;129;148)	21.6 (14.1 to 33.1)	24.8 (15.5 to 39.5)	56.5 (36.4 to 87.7)	
Opsono-19A, M12 (N=150;146;158)	12.6 (9.5 to 16.7)	9.1 (7 to 11.9)	9.6 (7.1 to 12.9)	

Statistical analyses

No statistical analyses for this end point

Secondary: Concentrations of antibodies against protein D (Anti-PD) - 12 months after booster dose.

End point title	Concentrations of antibodies against protein D (Anti-PD) - 12 months after booster dose.
-----------------	--

End point description:

A seropositive subject was a subject whose antibody concentration was greater than or equal to the cut-off value ≥ 100 EL.U/mL

End point type	Secondary
----------------	-----------

End point timeframe:

12 months after the administration of the booster dose (at 23-25 months of age, M12)

End point values	10Pn+DTPa- HBV-IPV/Hib Group	10Pn+DTPa- IPV-Hib Group	7Pn+DTPa- IPV-Hib Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	168	170	178	
Units: EL.U/mL				
geometric mean (confidence interval 95%)				
Anti-PD, M12 (N=168;170;178)	332 (287.1 to 384)	423 (359.9 to 497.1)	81.4 (73.1 to 90.6)	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with positive cultures of Haemophilus Influenzae and/or Streptococcus Pneumoniae in the Nasopharynx - Primary vaccination.

End point title	Number of subjects with positive cultures of Haemophilus Influenzae and/or Streptococcus Pneumoniae in the
-----------------	--

End point description:

Positive cultures of H. influenza* (HI) and S. pneumonia (SP) identified in the nasopharynx one month after the third dose of primary vaccination.

*Data presented only include results from samples confirmed as positive for H. influenzae / Non-typeable H. influenzae after differentiation from H. haemolyticus by Polymerase Chain Reaction (PCR) assay

End point type	Secondary
----------------	-----------

End point timeframe:

One month after the third dose

End point values	10Pn+DTPa- HBV-IPV/Hib Group	10Pn+DTPa- IPV-Hib Group	7Pn+DTPa- IPV-Hib Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	260	259	259	
Units: Subjects				
Any SP (N=260;259;259)	102	109	100	
Any HI (N=259;258;258)	94	91	85	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with positive cultures of Haemophilus Influenzae and/or Streptococcus Pneumoniae in the Nasopharynx - Booster vaccination.

End point title	Number of subjects with positive cultures of Haemophilus Influenzae and/or Streptococcus Pneumoniae in the Nasopharynx - Booster vaccination.
-----------------	---

End point description:

Positive cultures of H. influenza* (HI) and S. pneumonia (SP) identified in the nasopharynx at each swab time point: pre-booster vaccination (11-13 months of age), M3 (14-16 months of age), M7 (18-20 months of age) and M12 (23-25 months of age).

*Data presented only include results from samples confirmed as positive for H. influenzae / Non-typeable H. influenzae after differentiation from H. haemolyticus by Polymerase Chain Reaction (PCR) assay

End point type	Secondary
----------------	-----------

End point timeframe:

Prior to the booster dose (PRE), at 14-16 months of age (3 months after the booster dose - M3), at 18-20 months of age (7 months after the booster dose - M7) and at 23-25 months of age (12 months after the booster dose - M12)

End point values	10Pn+DTPa- HBV-IPV/Hib Group	10Pn+DTPa- IPV-Hib Group	7Pn+DTPa- IPV-Hib Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	256	259	258	
Units: Subjects				
Any SP, PRE (N=255;259;258)	115	134	119	
Any SP, M3 (N=256;258;257)	121	131	126	
Any SP, M7 (N=256;258;258)	151	135	148	
Any SP, M12 (N=255;257;257)	154	139	131	
Any HI, PRE (N=254;258;256)	152	155	144	
Any HI, M3 (N=256;258;257)	159	160	165	
Any HI, M7 (N=252;258;256)	185	169	162	
Any HI, M12 (N=254;255;254)	192	192	177	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with positive cultures of Streptococcus Pneumoniae vaccine serotypes (VS), cross-reactive serotypes (CRS) or other serotypes (OS) in the Nasopharynx - Primary vaccination.

End point title	Number of subjects with positive cultures of Streptococcus Pneumoniae vaccine serotypes (VS), cross-reactive serotypes (CRS) or other serotypes (OS) in the Nasopharynx - Primary vaccination.
-----------------	--

End point description:

Positive cultures of S. pneumonia (SP) identified in the nasopharynx one month after the third dose of primary vaccination.

End point type	Secondary
----------------	-----------

End point timeframe:

One month after the third dose

End point values	10Pn+DTPa- HBV-IPV/Hib Group	10Pn+DTPa- IPV-Hib Group	7Pn+DTPa- IPV-Hib Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	260	259	259	
Units: Subjects				
S. pneumoniae, VS (N=260;259;259)	18	25	21	
S. pneumoniae, CRS (N=260;259;259)	25	32	20	
S. pneumoniae, OS (N=260;259;259)	45	40	51	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with positive cultures of Streptococcus Pneumoniae vaccine serotypes (VS), cross-reactive serotypes (CRS) or other serotypes (OS) in the Nasopharynx - Booster vaccination.

End point title	Number of subjects with positive cultures of Streptococcus Pneumoniae vaccine serotypes (VS), cross-reactive serotypes (CRS) or other serotypes (OS) in the Nasopharynx - Booster vaccination.
-----------------	--

End point description:

Positive cultures of *S. pneumonia* (SP) identified in the nasopharynx at each swab time point: pre-booster vaccination (11-13 months of age), M3 (14-16 months of age), M7 (18-20 months of age) and M12 (23-25 months of age).

End point type	Secondary
----------------	-----------

End point timeframe:

Prior to the booster dose (PRE), at 14-16 months of age (3 months after the booster dose - M3), at 18-20 months of age (7 months after the booster dose - M7) and at 23-25 months of age (12 months after the booster dose - M12)

End point values	10Pn+DTPa-HBV-IPV/Hib Group	10Pn+DTPa-IPV-Hib Group	7Pn+DTPa-IPV-Hib Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	256	259	258	
Units: Subjects				
S. pneumoniae, VS PRE (N=255;259;257)	16	20	18	
S. pneumoniae, VS M3 (N=256;258;257)	11	18	13	
S. pneumoniae, VS M7 (N=256;258;258)	15	12	12	
S. pneumoniae, VS M12 (N=255;257;257)	8	8	8	
S. pneumoniae, CRS PRE (N=255;259;257)	15	30	25	
S. pneumoniae, CRS M3 (N=256;258;257)	25	26	27	
S. pneumoniae, CRS M7 (N=256;258;258)	33	33	31	
S. pneumoniae, CRS M12 (N=255;257;257)	28	13	25	
S. pneumoniae, OS PRE (N=255;259;257)	69	61	60	
S. pneumoniae, OS M3 (N=256;258;257)	74	69	70	
S. pneumoniae, OS M7 (N=256;258;258)	86	67	89	
S. pneumoniae, OS M12 (N=255;257;257)	97	81	80	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with acquisition of new Streptococcus pneumoniae

and Haemophilus Influenzae strains identified in nasopharyngeal swabs

End point title	Number of subjects with acquisition of new Streptococcus pneumoniae and Haemophilus Influenzae strains identified in nasopharyngeal swabs
-----------------	---

End point description:

Acquisition of new H. influenza* (HI) and S. pneumonia (SP) strains, identified in the nasopharynx at each swab time point: pre-booster vaccination (11-13 months of age), M3 (14-16 months of age), M7 (18-20 months of age) and M12 (23-25 months of age).

*Data presented only include results from samples confirmed as positive for H. influenzae / Non-typeable H. influenzae after differentiation from H. haemolyticus by Polymerase Chain Reaction (PCR) assay

End point type	Secondary
----------------	-----------

End point timeframe:

Prior to the booster dose (PRE), at 14-16 months of age (3 months after the booster dose - M3), at 18-20 months of age (7 months after the booster dose - M7) and at 23-25 months of age (12 months after the booster dose - M12)

End point values	10Pn+DTPa-HBV-IPV/Hib Group	10Pn+DTPa-IPV-Hib Group	7Pn+DTPa-IPV-Hib Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	256	259	258	
Units: Subjects				
Any SP, PRE (N=255;259;258)	103	114	107	
Any SP, M3 (N=256;258;257)	86	95	90	
Any SP, M7 (N=256;258;258)	128	105	125	
Any SP, M12 (N=255;257;257)	132	113	110	
Any HI, PRE (N=254;258;256)	88	84	83	
Any HI, M3 (N=256;258;257)	47	48	58	
Any HI, M7 (N=252;258;256)	71	55	64	
Any HI, M12 (N=254;255;254)	73	75	71	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with acquisition of new Streptococcus pneumoniae vaccine serotypes (VS), cross-reactive serotypes (CRS) or other serotypes (OS) identified in nasopharyngeal swabs

End point title	Number of subjects with acquisition of new Streptococcus pneumoniae vaccine serotypes (VS), cross-reactive serotypes (CRS) or other serotypes (OS) identified in nasopharyngeal swabs
-----------------	---

End point description:

Acquisition of new S. pneumonia (SP) strains, identified in the nasopharynx at each swab time point: pre-booster vaccination (11-13 months of age), M3 (14-16 months of age), M7 (18-20 months of age) and M12 (23-25 months of age).

End point type	Secondary
----------------	-----------

End point timeframe:

Prior to the booster dose (PRE), at 14-16 months of age (3 months after the booster dose - M3), at 18-

End point values	10Pn+DTPa- HBV-IPV/Hib Group	10Pn+DTPa- IPV-Hib Group	7Pn+DTPa- IPV-Hib Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	256	259	258	
Units: Subjects				
S. pneumoniae, VS PRE (N=255;259;257)	14	11	15	
S. pneumoniae, VS M3 (N=256;258;257)	8	9	8	
S. pneumoniae, VS M7 (N=256;258;258)	13	7	9	
S. pneumoniae, VS M12 (N=255;257;257)	4	7	6	
S. pneumoniae, CRS PRE (N=255;259;257)	13	26	20	
S. pneumoniae, CRS M3 (N=256;258;257)	19	15	20	
S. pneumoniae, CRS M7 (N=256;258;258)	27	25	24	
S. pneumoniae, CRS M12 (N=255;257;257)	22	8	18	
S. pneumoniae, OS PRE (N=255;259;257)	64	55	57	
S. pneumoniae, OS M3 (N=256;258;257)	52	59	52	
S. pneumoniae, OS M7 (N=256;258;258)	74	55	77	
S. pneumoniae, OS M12 (N=255;257;257)	87	69	69	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with solicited local symptoms - Primary vaccination

End point title	Number of subjects with solicited local symptoms - Primary vaccination
End point description:	
Solicited local symptoms assessed were pain, redness and swelling. Any was defined as any occurrence of the specified symptom regardless of intensity. Grade 3 pain was defined as cried when limb was moved/spontaneously painful. Grade 3 redness/swelling was defined as redness/swelling > 30 millimetres from injection site.	
End point type	Secondary
End point timeframe:	
Within 4 days (Day 0 - Day 3) post-primary vaccination across the 3 doses.	

End point values	10Pn+DTPa- HBV-IPV/Hib Group	10Pn+DTPa- IPV-Hib Group	7Pn+DTPa- IPV-Hib Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	260	260	260	
Units: Subjects				
Any Pain, PRI (N=260;260;260)	205	193	178	
Grade 3 Pain, PRI (N=260;260;260)	42	40	29	
Any Redness, PRI (N=260;260;260)	197	193	184	
Grade 3 Redness, PRI (N=260;260;260)	12	26	19	
Any Swelling, PRI (N=260;260;260)	205	199	179	
Grade 3 Swelling, PRI (N=260;260;260)	18	29	24	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with solicited general symptoms - Primary vaccination

End point title	Number of subjects with solicited general symptoms - Primary vaccination
-----------------	--

End point description:

Solicited general symptoms assessed include drowsiness, fever (defined as rectal temperature $\geq 38.0^{\circ}\text{C}$), irritability, and loss of appetite. Grade 3 drowsiness was defined as drowsiness which prevented normal everyday activities. Grade 3 fever was defined as fever (rectal temperature) above ($>$) 40.0 degree Celsius ($^{\circ}\text{C}$). Grade 3 irritability was defined as crying that could not be comforted/preventing normal activity. Grade 3 loss of appetite was defined as the subject not eating at all. "Any" is defined as incidence of the specified symptom regardless of intensity.

End point type	Secondary
----------------	-----------

End point timeframe:

Within 4 days (Day 0 - Day 3) post-primary vaccination across the 3 doses.

End point values	10Pn+DTPa- HBV-IPV/Hib Group	10Pn+DTPa- IPV-Hib Group	7Pn+DTPa- IPV-Hib Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	260	260	260	
Units: Subjects				
Any Drowsiness, PRI (N=260; 260;260)	231	220	215	
Grade 3 Drowsiness, PRI (N=260; 260;260)	14	13	7	
Any Temperature, PRI (N=260; 260;260)	153	124	110	
Grade 3 Temperature, PRI (N=260; 260;260)	0	0	0	
Any Irritability, PRI (N=260; 260;260)	241	230	235	
Grade 3 Irritability, PRI (N=260; 260;260)	42	37	16	
Any Loss of appetite, PRI (N=260; 260;260)	155	145	153	

Grade 3 Loss of appetite, PRI (N=260; 260;260)	4	4	1	
--	---	---	---	--

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with unsolicited adverse events (AEs) - Primary vaccination.

End point title	Number of subjects with unsolicited adverse events (AEs) - Primary vaccination.
-----------------	---

End point description:

An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. "Any" is defined an incidence of an unsolicited AE regardless of intensity or relationship to study vaccination.

End point type	Secondary
----------------	-----------

End point timeframe:

Within 31 days (Day 0 - Day 30) after each primary vaccination.

End point values	10Pn+DTPa- HBV-IPV/Hib Group	10Pn+DTPa- IPV-Hib Group	7Pn+DTPa- IPV-Hib Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	260	260	260	
Units: Subjects				
Subject(s) with AE(s), PRI	181	177	185	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with serious adverse events (SAEs)

End point title	Number of subjects with serious adverse events (SAEs)
-----------------	---

End point description:

SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects.

End point type	Secondary
----------------	-----------

End point timeframe:

Throughout the entire study period

End point values	10Pn+DTPa- HBV-IPV/Hib Group	10Pn+DTPa- IPV-Hib Group	7Pn+DTPa- IPV-Hib Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	260	260	260	
Units: Subjects				
Subject(s) with SAE(s)	35	26	35	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with solicited local symptoms -Booster vaccination

End point title	Number of subjects with solicited local symptoms -Booster vaccination
-----------------	---

End point description:

Solicited local symptoms assessed were pain, redness and swelling. Any was defined as any occurrence of the specified symptom regardless of intensity. Grade 3 pain was defined as cried when limb was moved/spontaneously painful. Grade 3 redness/swelling was defined as redness/swelling > 30 millimetres from injection site.

End point type	Secondary
----------------	-----------

End point timeframe:

Within 4 days (Day 0 - Day 3) after the booster vaccination.

End point values	10Pn+DTPa- HBV-IPV/Hib Group	10Pn+DTPa- IPV-Hib Group	7Pn+DTPa- IPV-Hib Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	257	258	258	
Units: Subjects				
Any Pain, BST (N=257;258; 258)	174	161	145	
Grade 3 Pain, BST (N=257;258; 258)	21	21	7	
Any Redness, BST (N=257;258; 258)	175	144	180	
Grade 3 Redness, BST (N=257;258; 258)	22	10	10	
Any Swelling, BST (N=257;258; 258)	185	146	160	
Grade 3 Swelling, BST (N=257;258; 258)	27	15	11	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with solicited general symptoms - Booster vaccination.

End point title	Number of subjects with solicited general symptoms - Booster vaccination.
-----------------	---

End point description:

Solicited general symptoms assessed include drowsiness, fever (defined as rectal temperature $\geq 38.0^{\circ}\text{C}$), irritability, and loss of appetite. Grade 3 drowsiness was defined as drowsiness which prevented normal everyday activities. Grade 3 fever was defined as fever (rectal temperature) above ($>$) 40.0°C . Grade 3 irritability was defined as crying that could not be comforted/preventing normal activity. Grade 3 loss of appetite was defined as the subject not eating at all. "Any" is defined as incidence of the specified symptom regardless of intensity.

End point type	Secondary
----------------	-----------

End point timeframe:

Within 4 days (Day 0 - Day 3) after booster vaccination.

End point values	10Pn+DTPa-HBV-IPV/Hib Group	10Pn+DTPa-IPV-Hib Group	7Pn+DTPa-IPV-Hib Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	256	258	258	
Units: Subjects				
Any Drowsiness, BST (N=256; 258;258)	131	118	128	
Grade 3 Drowsiness, BST (N=256; 258;258)	6	5	3	
Any Temperature, BST (N=256; 258;258)	100	100	103	
Grade 3 Temperature, BST (N=256; 258;258)	1	2	1	
Any Irritability, BST (N=256; 258;258)	167	161	166	
Grade 3 Irritability, BST (N=256; 258;258)	11	8	1	
Any Loss of appetite, BST (N=256; 258;258)	93	83	111	
Grade 3 Loss of appetite, BST dose (N=256; 258;258)	5	0	2	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with unsolicited adverse events (AEs) - Booster vaccination.

End point title	Number of subjects with unsolicited adverse events (AEs) - Booster vaccination.
-----------------	---

End point description:

An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. "Any" is defined as incidence of an unsolicited AE regardless of intensity or relationship to study vaccination.

End point type	Secondary
----------------	-----------

End point timeframe:

Within 31 days (Day 0 - Day 30) after booster vaccination.

End point values	10Pn+DTPa- HBV-IPV/Hib Group	10Pn+DTPa- IPV-Hib Group	7Pn+DTPa- IPV-Hib Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	257	259	258	
Units: Subjects				
Subject(s) with AE(s), BST	106	105	105	

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Solicited & Unsolicited AEs: During the 4-and 31-days period(s) post primary (PRI) or booster (BST) vaccinations, respectively; SAEs: from study start to study end

Adverse event reporting additional description:

The occurrence of reported AEs (all/related) was not available and is encoded as equal to the number of subjects affected.

Assessment type	Non-systematic
-----------------	----------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	14.0
--------------------	------

Reporting groups

Reporting group title	10Pn+DTPa-HBV-IPV/Hib Group
-----------------------	-----------------------------

Reporting group description:

Subjects received 3 doses of 10Pn-PD-DiT (or GSK1024850A) vaccine co-administered with DTPa-HBV-IPV/Hib vaccine (Infanrix hexa by GSK Biologicals) at 2, 3 and 4 months of age (Study Months 0, 1, 2) and received a booster dose of each vaccine between 11 and 13 months of age (Study Month 9). All vaccines were administered intramuscularly in the right (10Pn-PD-DiT) or left (DTPa-HBV-IPV/Hib) thigh or deltoid.

Reporting group title	10Pn+DTPa-IPV-Hib Group
-----------------------	-------------------------

Reporting group description:

Subjects received 3 doses of 10Pn-PD-DiT (or GSK1024850A) vaccine co-administered with DTPa-IPV-Hib vaccine (PediaceL by Sanofi Pasteur MSD) at 2, 3 and 4 months of age (Study Months 0, 1, 2) and received a booster dose of each vaccine between 11 and 13 months of age (Study Month 9). All vaccines were administered intramuscularly in the right (10Pn-PD-DiT) or left (DTPa-IPV-Hib) thigh or deltoid.

Reporting group title	7Pn+DTPa-IPV-Hib Group
-----------------------	------------------------

Reporting group description:

Subjects received 3 doses of 7Pn vaccine (or Prevenar by Pfizer [formerly Wyeth Lederle Vaccines S.A.]) co-administered with DTPa-IPV-Hib vaccine (PediaceL by Sanofi Pasteur MSD) at 2, 3 and 4 months of age (Study Months 0, 1, 2) and received a booster dose of each vaccine between 11 and 13 months of age (Study Month 9). All vaccines were administered intramuscularly in the right (10Pn; 7Pn) or left (DTPa-IPV-Hib; DTPa-HBV-IPV/Hib) thigh or deltoid.

Serious adverse events	10Pn+DTPa-HBV-IPV/Hib Group	10Pn+DTPa-IPV-Hib Group	7Pn+DTPa-IPV-Hib Group
Total subjects affected by serious adverse events			
subjects affected / exposed	35 / 260 (13.46%)	26 / 260 (10.00%)	35 / 260 (13.46%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
Injury, poisoning and procedural complications			
Concussion			
subjects affected / exposed	3 / 260 (1.15%)	2 / 260 (0.77%)	2 / 260 (0.77%)
occurrences causally related to treatment / all	0 / 3	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Greenstick fracture			

subjects affected / exposed	0 / 260 (0.00%)	1 / 260 (0.38%)	0 / 260 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Poisoning			
subjects affected / exposed	1 / 260 (0.38%)	0 / 260 (0.00%)	0 / 260 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thermal burn			
subjects affected / exposed	0 / 260 (0.00%)	0 / 260 (0.00%)	1 / 260 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Haematoma			
subjects affected / exposed	0 / 260 (0.00%)	1 / 260 (0.38%)	0 / 260 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital, familial and genetic disorders			
Velo-cardio-facial syndrome			
subjects affected / exposed	0 / 260 (0.00%)	0 / 260 (0.00%)	1 / 260 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Convulsion			
subjects affected / exposed	0 / 260 (0.00%)	1 / 260 (0.38%)	1 / 260 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile convulsion			
subjects affected / exposed	0 / 260 (0.00%)	0 / 260 (0.00%)	1 / 260 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Status epilepticus			
subjects affected / exposed	0 / 260 (0.00%)	1 / 260 (0.38%)	0 / 260 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

General disorders and administration site conditions			
Adhesion			
subjects affected / exposed	0 / 260 (0.00%)	1 / 260 (0.38%)	0 / 260 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	1 / 260 (0.38%)	1 / 260 (0.38%)	0 / 260 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Lymphadenitis			
subjects affected / exposed	1 / 260 (0.38%)	0 / 260 (0.00%)	0 / 260 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Coeliac disease			
subjects affected / exposed	0 / 260 (0.00%)	0 / 260 (0.00%)	1 / 260 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroesophageal reflux disease			
subjects affected / exposed	1 / 260 (0.38%)	0 / 260 (0.00%)	1 / 260 (0.38%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal obstruction			
subjects affected / exposed	0 / 260 (0.00%)	1 / 260 (0.38%)	0 / 260 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal stenosis			
subjects affected / exposed	0 / 260 (0.00%)	1 / 260 (0.38%)	0 / 260 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intussusception			

subjects affected / exposed	0 / 260 (0.00%)	2 / 260 (0.77%)	0 / 260 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 260 (0.00%)	1 / 260 (0.38%)	0 / 260 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Apparent life threatening event			
subjects affected / exposed	2 / 260 (0.77%)	1 / 260 (0.38%)	0 / 260 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchial hyperreactivity			
subjects affected / exposed	2 / 260 (0.77%)	1 / 260 (0.38%)	4 / 260 (1.54%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchospasm			
subjects affected / exposed	1 / 260 (0.38%)	0 / 260 (0.00%)	0 / 260 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Status asthmaticus			
subjects affected / exposed	0 / 260 (0.00%)	0 / 260 (0.00%)	1 / 260 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Hyperhidrosis			
subjects affected / exposed	1 / 260 (0.38%)	0 / 260 (0.00%)	0 / 260 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Bronchiolitis			
subjects affected / exposed	3 / 260 (1.15%)	1 / 260 (0.38%)	1 / 260 (0.38%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Bronchopneumonia			
subjects affected / exposed	1 / 260 (0.38%)	0 / 260 (0.00%)	0 / 260 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	1 / 260 (0.38%)	0 / 260 (0.00%)	0 / 260 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterovirus infection			
subjects affected / exposed	1 / 260 (0.38%)	0 / 260 (0.00%)	1 / 260 (0.38%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	8 / 260 (3.08%)	4 / 260 (1.54%)	5 / 260 (1.92%)
occurrences causally related to treatment / all	0 / 8	0 / 4	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis adenovirus			
subjects affected / exposed	1 / 260 (0.38%)	1 / 260 (0.38%)	0 / 260 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis norovirus			
subjects affected / exposed	0 / 260 (0.00%)	1 / 260 (0.38%)	0 / 260 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis rotavirus			
subjects affected / exposed	1 / 260 (0.38%)	2 / 260 (0.77%)	2 / 260 (0.77%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis viral			
subjects affected / exposed	0 / 260 (0.00%)	1 / 260 (0.38%)	1 / 260 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intervertebral discitis			

subjects affected / exposed	0 / 260 (0.00%)	0 / 260 (0.00%)	1 / 260 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection viral			
subjects affected / exposed	0 / 260 (0.00%)	0 / 260 (0.00%)	1 / 260 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mastoiditis			
subjects affected / exposed	0 / 260 (0.00%)	0 / 260 (0.00%)	1 / 260 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningitis			
subjects affected / exposed	0 / 260 (0.00%)	1 / 260 (0.38%)	0 / 260 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oral herpes			
subjects affected / exposed	1 / 260 (0.38%)	0 / 260 (0.00%)	1 / 260 (0.38%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Otitis media			
subjects affected / exposed	3 / 260 (1.15%)	0 / 260 (0.00%)	1 / 260 (0.38%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	1 / 260 (0.38%)	2 / 260 (0.77%)	3 / 260 (1.15%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia primary atypical			
subjects affected / exposed	0 / 260 (0.00%)	0 / 260 (0.00%)	1 / 260 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			

subjects affected / exposed	1 / 260 (0.38%)	0 / 260 (0.00%)	3 / 260 (1.15%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory syncytial virus bronchiolitis			
subjects affected / exposed	5 / 260 (1.92%)	2 / 260 (0.77%)	5 / 260 (1.92%)
occurrences causally related to treatment / all	0 / 5	0 / 2	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory syncytial virus bronchitis			
subjects affected / exposed	1 / 260 (0.38%)	0 / 260 (0.00%)	0 / 260 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	1 / 260 (0.38%)	1 / 260 (0.38%)	4 / 260 (1.54%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 260 (0.00%)	2 / 260 (0.77%)	0 / 260 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral upper respiratory tract infection			
subjects affected / exposed	0 / 260 (0.00%)	0 / 260 (0.00%)	1 / 260 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 260 (0.00%)	1 / 260 (0.38%)	0 / 260 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Feeding disorder neonatal			
subjects affected / exposed	0 / 260 (0.00%)	1 / 260 (0.38%)	0 / 260 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	10Pn+DTPa-HBV- IPV/Hib Group	10Pn+DTPa-IPV-Hib Group	7Pn+DTPa-IPV-Hib Group
Total subjects affected by non-serious adverse events			
subjects affected / exposed	241 / 260 (92.69%)	230 / 260 (88.46%)	235 / 260 (90.38%)
General disorders and administration site conditions			
Pyrexia - BST			
subjects affected / exposed ^[1]	16 / 257 (6.23%)	13 / 259 (5.02%)	21 / 258 (8.14%)
occurrences (all)	16	13	21
Pain - PRI			
alternative dictionary used: MedDRA 12.1			
alternative assessment type: Systematic			
subjects affected / exposed	205 / 260 (78.85%)	193 / 260 (74.23%)	178 / 260 (68.46%)
occurrences (all)	205	193	178
Redness - PRI			
alternative dictionary used: MedDRA 12.1			
alternative assessment type: Systematic			
subjects affected / exposed	197 / 260 (75.77%)	193 / 260 (74.23%)	184 / 260 (70.77%)
occurrences (all)	197	193	184
Swelling - PRI			
alternative dictionary used: MedDRA 12.1			
alternative assessment type: Systematic			
subjects affected / exposed	205 / 260 (78.85%)	199 / 260 (76.54%)	179 / 260 (68.85%)
occurrences (all)	205	199	179
Pain - BST			
alternative assessment type: Systematic			
subjects affected / exposed ^[2]	174 / 257 (67.70%)	161 / 258 (62.40%)	145 / 258 (56.20%)
occurrences (all)	174	161	145
Redness - BST			
alternative assessment type: Systematic			
subjects affected / exposed ^[3]	175 / 257 (68.09%)	144 / 258 (55.81%)	180 / 258 (69.77%)
occurrences (all)	175	144	180
Swelling - BST			
alternative assessment type: Systematic			

subjects affected / exposed ^[4]	185 / 257 (71.98%)	146 / 258 (56.59%)	160 / 258 (62.02%)
occurrences (all)	185	146	160
Drowsiness - PRI			
alternative dictionary used:			
MedDRA 12.1			
alternative assessment type:			
Systematic			
subjects affected / exposed	231 / 260 (88.85%)	220 / 260 (84.62%)	215 / 260 (82.69%)
occurrences (all)	231	220	215
Rectal Temperature >=38.0°C - PRI			
alternative dictionary used:			
MedDRA 12.1			
alternative assessment type:			
Systematic			
subjects affected / exposed	153 / 260 (58.85%)	124 / 260 (47.69%)	110 / 260 (42.31%)
occurrences (all)	153	124	110
Irritability - PRI			
alternative dictionary used:			
MedDRA 12.1			
alternative assessment type:			
Systematic			
subjects affected / exposed	241 / 260 (92.69%)	230 / 260 (88.46%)	235 / 260 (90.38%)
occurrences (all)	241	230	235
Loss of appetite - PRI			
alternative dictionary used:			
MedDRA 12.1			
alternative assessment type:			
Systematic			
subjects affected / exposed	155 / 260 (59.62%)	145 / 260 (55.77%)	153 / 260 (58.85%)
occurrences (all)	155	145	153
Drowsiness – BST			
alternative assessment type:			
Systematic			
subjects affected / exposed ^[5]	131 / 256 (51.17%)	118 / 258 (45.74%)	128 / 258 (49.61%)
occurrences (all)	131	118	128
Rectal Temperature >=38.0°C – BST			
alternative assessment type:			
Systematic			
subjects affected / exposed ^[6]	100 / 256 (39.06%)	100 / 258 (38.76%)	103 / 258 (39.92%)
occurrences (all)	100	100	103
Irritability – BST			
alternative assessment type:			
Systematic			
subjects affected / exposed ^[7]	167 / 256 (65.23%)	161 / 258 (62.40%)	166 / 258 (64.34%)
occurrences (all)	167	161	166

Loss of appetite - BST alternative assessment type: Systematic subjects affected / exposed ^[8] occurrences (all)	93 / 256 (36.33%) 93	83 / 258 (32.17%) 83	111 / 258 (43.02%) 111
Gastrointestinal disorders Diarrhoea - PRI alternative dictionary used: MedDRA 12.1 subjects affected / exposed occurrences (all) Vomiting - PRI alternative dictionary used: MedDRA 12.1 subjects affected / exposed occurrences (all)	15 / 260 (5.77%) 15 11 / 260 (4.23%) 11	14 / 260 (5.38%) 14 13 / 260 (5.00%) 13	12 / 260 (4.62%) 12 0 / 260 (0.00%) 0
Respiratory, thoracic and mediastinal disorders Wheezing - PRI alternative dictionary used: MedDRA 12.1 subjects affected / exposed occurrences (all)	15 / 260 (5.77%) 15	7 / 260 (2.69%) 7	10 / 260 (3.85%) 10
Skin and subcutaneous tissue disorders Eczema - PRI alternative dictionary used: MedDRA 12.1 subjects affected / exposed occurrences (all)	24 / 260 (9.23%) 24	15 / 260 (5.77%) 15	18 / 260 (6.92%) 18
Infections and infestations Upper respiratory tract infection - PRI alternative dictionary used: MedDRA 12.1 subjects affected / exposed occurrences (all) Gastroenteritis - PRI alternative dictionary used: MedDRA 12.1 subjects affected / exposed occurrences (all) Viral infection - BST subjects affected / exposed ^[9] occurrences (all)	99 / 260 (38.08%) 99 16 / 260 (6.15%) 16 5 / 257 (1.95%) 5	108 / 260 (41.54%) 108 13 / 260 (5.00%) 13 17 / 259 (6.56%) 17	111 / 260 (42.69%) 111 13 / 260 (5.00%) 13 5 / 258 (1.94%) 5

Upper respiratory tract infection - BST			
subjects affected / exposed ^[10]	27 / 257 (10.51%)	32 / 259 (12.36%)	34 / 258 (13.18%)
occurrences (all)	27	32	34

Notes:

[1] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Assessment for this event for this specified phase was performed solely on subjects with available results.

[2] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Assessment for this event for this specified phase was performed solely on subjects with available results.

[3] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Assessment for this event for this specified phase was performed solely on subjects with available results.

[4] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Assessment for this event for this specified phase was performed solely on subjects with available results.

[5] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Assessment for this event for this specified phase was performed solely on subjects with available results.

[6] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Assessment for this event for this specified phase was performed solely on subjects with available results.

[7] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Assessment for this event for this specified phase was performed solely on subjects with available results.

[8] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Assessment for this event for this specified phase was performed solely on subjects with available results.

[9] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Assessment for this event for this specified phase was performed solely on subjects with available results.

[10] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Assessment for this event for this specified phase was performed solely on subjects with available results.

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
22 November 2007	A first amendment was made to the protocol in response to comments from the Dutch Authorities to clarify that this study was a single-centre study.
30 January 2008	On request of the Dutch Authorities, a second amendment to the protocol was made. Changes concerned the study design: 1) Before vaccination at Visit 1 no blood sample was to be collected; 2) The priority ranking for testing of opsonophagocytic activity (OPA) activity against the 10 pneumococcal vaccine serotypes in case of insufficient blood sample volume was changed; 3) Testing of OPA activity against the 10 pneumococcal vaccine serotypes was to be done for all subjects i.e. all subjects for which the amount of remaining/available serum is sufficient; 4) The sample size was increased.
14 August 2008	Changes concerned the study design: 1) To collect information about factors that could potentially influence nasopharyngeal carriage of Streptococcus (S.) pneumoniae and Haemophilus (H.) influenzae, it was planned that the subjects' parents/ guardian(s) would be asked some questions at Visits 4, 5, 7, 8 and 9; 2) The recruitment period was changed to 9 months.
22 March 2010	The following changes were introduced: 1) Due to the H1N1 influenza pandemic, the children were offered H1N1 influenza vaccine as part of a national pandemic prevention plan. Thus, the age range for the booster vaccination visit and subsequent visits was extended; 2) Further details on microbiological testing were included; 3) A second Interim Analysis was added to evaluate carriage (at 3 timepoints) using classical methods for bacterial identification / typing, additional microbiological techniques for H. influenzae/H. haemolyticus discrimination and quantitative molecular techniques for H. influenzae carriage; 4) The back-up contact details for reporting SAEs were updated.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported